ПОКРЫТИЕ ДЛЯ ИНТРАЛЮМИНАЛЬНОГО РАСШИРЯЮЩЕГОСЯ КАТЕТЕРА, ОБЕСПЕЧИВАЮЩЕЕ КОНТАКТНУЮ ДОСТАВКУ МИКРОРЕЗЕРВУАРОВ С ЛЕКАРСТВЕННЫМ СРЕДСТВОМ

Группа изобретений раскрывает катетер с покрытием на расширяемой части катетера, способ нанесения покрытия на расширяемую часть катетера и способ доставки активного агента к участку лечения. Покрывающий состав, который наносится на расширяемую часть катетера, характеризуется тем, что содержит гидрофобную матрицу и диспергированную фазу. Диспергированная фаза содержит множество микрорезервуаров, диспергированных в гидрофобной матрице, при этом множество микрорезервуаров содержит активный агент и биоразлагаемый полимер. Группа изобретений позволяет облегчать доставку лекарственных средств к поврежденным сосудам. 5 н. и 63 з.п. ф-лы, 5 ил., 13 пр., 19 табл.

ПЛАСТЫРЬ, СОДЕРЖАЩИЙ ЭКСТРАКТ ЛУКА

ДОСТАВКА ЧАСТИЦ ГИДРОФОБНОГО АКТИВНОГО СРЕДСТВА

ВОССТАНОВЛЕНИЕ КРОВОТОКА В ЗАБЛОКИРОВАННЫХ АРТЕРИЯХ ЧЕЛОВЕКА ПУТЕМ ПЕРЕНОСА НАНОИНКАПСУЛИРОВАННОГО ЛЕКАРСТВЕННОГО СРЕДСТВА ПОСРЕДСТВОМ МЕДИЦИНСКИХ УСТРОЙСТВ, РАЗРАБОТАННЫХ ДЛЯ ЭТОГО, И ВЫСВОБОЖДЕНИЯ НАНОИНКАПСУЛИРОВАННОГО СРЕДСТВА В АРТЕРИИ ЧЕЛОВЕКА ПРИ УРОВНЕ pН ОРГАНИЗМА

... 1. Доставляющее лекарственное средство вводимое медицинское устройство для лечения медицинского состояния, связанного с просветом части организма, при этом просвет части организма имеет границы с множеством слоев, причем доставляющее лекарственное средство вводимое медицинское устройство имеет:внешнюю поверхность, покрытую множеством наноносителей, имеющих множество средних диаметров, при этом наноноситель из множества наноносителей содержит лекарственное средство, окруженное инкапсулирующей средой, где инкапсулирующая среда содержит по меньшей мере одно из биологического средства, наполнителя на основе крови и фосфолипида, при этом наноноситель имеет средний диаметр, приемлемый для проникновения сквозь по меньшей мере один слой из множества слоев, и поверхность наноносителя свободна от лекарственного средства.2. Доставляющее лекарственное средство вводимое медицинское устройство по п.1, где множество наноносителей высвобождаются с внешней поверхности, и по меньшей мере один наноноситель ...

Medizinische Wirkstoffe freisetzende Beschichtungen für medizinische Vorrichtungen

Medizinisches Implantat mit Oberflächenbeschichtung

Medizinisches Implantat (1) mit einer Oberflächenbeschichtung zum Einsatz in einem lebenden Patienten, wobei die Oberflächenbeschichtung aus mindestens zwei übereinanderliegenden Trägerschichten (3, 4, 5) besteht, die jeweils mindestens einen pharmazeutisch aktiven Wirkstoff (W) tragen,dadurch gekennzeichnet,dass die Trägerschichten (3, 4, 5) im Serum des Patienten löslich sind, wodurch die Wirkstoffe (W) freisetzbar sind, unddass mindestens eine Trägerschicht (3, 4, 5) der Oberflächenbeschichtung mindestens eine flächige Aussparung aufweist.

Schichtstruktur zur Abgabe mindestens eines Wirkstoffs

Schichtstruktur zur Abgabe mindestens eines Wirkstoffs, wobei die Schichtstruktur aufweist: ein Trägersubstrat (100), eine Mehrzahl von Wirkstoffbereichen (101), die voneinander beabstandet auf dem Trägersubstrat (100) aufgebracht sind und den mindestens einen Wirkstoff enthalten, wobei jeder der Wirkstoffbereiche (101) rundum von nicht wirkstoffbelegten Zwischenbereichen (102) des Trägersubstrats umgeben ist, eine semipermeable Deckschicht (103), die auf das Trägersubstrat (100) und die darauf befindlichen Wirkstoffbereiche (101) aufgebracht ist und sowohl die Wirkstoffbereiche (101) als auch die nicht wirkstoffbelegten Zwischenbereiche (102) des Trägersubstrats überdeckt, wobei die semipermeable Deckschicht (103) in den nicht wirkstoffbelegten Zwischenbereichen (102) unmittelbar oder mittelbar auf dem Trägersubstrat (100) anhaftet, wobei jeder der Wirkstoffbereiche (101) rundum seitlich und von oben her von der semipermeablen Deckschicht (103) umschlossen ist, so dass sich Wirkstoffdepots ...

MEDIZINISCHE VORRICHTUNG

BESCHICHTETE MEDIZINISCHE GERÄTE

Verfahren zur Herstellung einer hydrophilen Beschichtung auf einem Substrat, sowie Substrate, insbesondere medizinische Geräte, mit verschleissbeständigen Beschichtungen

Medizinisches Implantat und Verfahren zur Herstellung eines solchen Implantats

Die Erfindung bezieht sich auf ein medizinisches Implantat mit einem Körper (10), der zumindest bereichsweise aus wenigstens einem biologisch abbaubaren, kristallinen Material hergestellt ist. Die Erfindung zeichnet sich dadurch aus, dass der Körper (10) wenigstens zwei verschiedene erste und zweite Bereiche (11, 12) aufweist, wobei das kristalline Material des ersten Bereichs (11) eine andere Korngröße aufweist, als das kristalline Material des zweiten Bereichs (12).

Coated Medical devices

Wound dressing

Wound dressing (1) incorporates a rubefacient or hyperemic substance (3) in such a disposition that, upon application of the dressing to a wound site (7) said substance (3) will be brought into contact with skin surrounding the wound site but not with the wound site itself. In this respect, central section (2) of the dressing (1) may be cut away to expose i.e. overlie the wound site. A different type of dressing may be inserted here. The layer of the rubefacient or hyperemic substance (3) may be sandwiched between a cover material (4) and an adhesive layer (5), or it may be incorporated into the adhesive layer or microencapsulated and dispersed through the adhesive layer.

Haemostatic pad

A haemostatic material 2 for stemming blood loss from a wound is mounted on a carrier layer 6, preferably by adhesive. The carrier may be a non-woven viscose material, woven gauze, a film, foam or sheet gel. The adhesive may form a separate layer 4 or it may be mixed with the haemostat (8, figure 2). The haemostatic material may be protected by a release layer (10, figure 3) and may be mounted on both sides of the carrier layer (figure 4). The haemostat may be biodegradable in the body and is preferably a polysaccharide or chitosan salt such as chitosan succinate in the form of granules of more than 74 microns diameter or short fibres of less than 7.5 mm length. It may include a medical surfactant such as lauric acid and an inert material such as alginate.

DRUG DELIVERY COLLAGEN-IMPREGNATED SYNTHETIC VASCULAR GRAFT

MERSCHICHTIGES ELASTOMER MATERIAL WITH A CHEMICAL ACTIVE SUBSTANCE AND ITS APPLICATIONS

ABLUMINALE, MULTI-LAYER ONES BESCHICHTUNGSKONSTRUKTE FOR ARZNEIMITELABGABE STENTS

POLYACRYLAT LAYER FOR IMPLANTIERBARE MEDICAL DEVICES

COATING WITH POLYMER DETENTION MATERIAL FOR A MEDICAL DEVICE AND MANUFACTURING PROCESS FOR IT

BIOCOMPATIBLE MULTI-FUNCTION COATINGS FOR INTRAVASKULÄRE DEVICES

TRANSDERMALES DELIVERY SYSTEM

PROCEDURE FOR THE PRODUCTION OF STORABLE IMPLANTS WITH A ULTRAHYDROPHILEN A SURFACE

DEVICE FOR EXTENDED RELEASE AND METHOD FOR EYEPIECES THE ADMINISTRATION OF CARBOANHYDRASE INHIBITORS

POLYACRYLATE OBERFLÄCHESCHICHT FOR IMPLANTIERBARE MEDICAL DEVICES

LOCAL, VASCULAR ADMINISTRATION OF 2METHOXYESTRADIOL IN COMBINATION WITH RAPAMYCIN FOR the PREVENTION OF RESTENOSE AFTER CONTAINER INJURIES

DEVICE FOR THE DELIVERY OF THERAPEUTIC MEANS WITH A SEPARATING PROTECTIVE LAYER

MEDICINE PRODUCTS WITH ACTIVE SUBSTANCE-SETTING FREE COATING

MEDICAL DEVICE WITH IMPROVED ADHESION BETWEEN POLYMERS A BERZUG AND A SUBSTRATE

SEPARATION OF SILVER LAYERS ON NON CONDUCTIVE SUBSTRATES

Procedure for the production of silver-containing layers on aluminum and its alloys

IMPLANT WITH ANTIBIOTIC LONG-TERM EFFECT

HEPARIN STENT

Bioactive stents for type II diabetics and methods for use thereof

Local vascular delivery of an adenosine A2A receptor agonist / phosphodiesterase inhibitor combination to reduce myocardial injury

A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized in combination with other therapeutic agents to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position, the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist alone or in combination with other therapeutic agents elute from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury.

Gradient coating for biomedical applications

H:\tb\Intrwovn\NRPortbl\DCC\TXB09264 L.docx-8/10/2015 The present invention provides a coating comprising a bioactive material and an antimicrobial agent, wherein the concentration of said antimicrobial agent varies throughout the thickness of the coating.

Haemostatic material

Immobilised biological entities

There is described ...

An implantable medical device

An implantable medical device, which comprises a device substrate, a coating on the substrate which includes a drug which is highly soluble in water, and a protective layer which overlies the coating. The protective layer comprises a polymer selected from the group consisting of polylactic acid, polyglycolic acid and a lactic acid/glycolic acid copolymer having a weight average molecular weight of not more than 40,000.

Wound dressing or dermal patch

The invention relates to a pharmaceutical composition and in particular a dermal patch or wound dressing comprising an acid-hydrolyzing oligomer and/or polymer and an acid-activated prodrug such that the active principle in the pharmaceutical composition or in the dermal patch or wound dressing is formed from the prodrug under the effect of acid. The invention further relates to a corresponding method for releasing active principles from a pharmaceutical composition.

COLLAGEN FILM DRUG DELIVERY FOR PROTEINS

INDWELLING STENT

As a therapy for angiostenosis, angioplasty (PTA, PTCA), in which a small balloon is inflated in a blood vessel to dilate the vessel, has been widely carried out as a minimally invasive treatment. In this therapy, however, repeated stenosis (restenosis) occurs at a high possibility. As a means of lessening the restenosis, procedures using indwelling stents become popular in recent years. However, it is reported that restenosis occurs at a frequency of about 20 to 30% even in these treatments using indwelling stents. Although attempts have been thus made to coat a stent with a drug regulating obstruction, stenosis still arises at a high frequency in such cases at the present stage. At least two layers involving a layer containing an immune suppressant and a layer containing an antiinflammatory agent are formed on the surface of an indwelling stent.

COATING MEDICAL DEVICES USING AIR SUSPENSION

Methods and apparatuses for coating medical devices and the devices thereby produced are disclosed. In one embodiment, the invention includes a method comprising the steps of suspending the medical device in an air stream and introducing a coating material into the air stream such that the coating material is dispersed therein and coats at least a portion of the medical device. In another embodiment, the medical devices are suspended in an air stream and a coating apparatus coats at least a portion of the medical device with a coating material. The coating apparatus may include a device that utilizes any number of alternative coating techniques for coating the medical devices. This process is used to apply one or more coating materials, simultaneously or in sequence. In certain embodiments of the invention, the coating materials include therapeutic agents, polymers, sugars, waxes, or fats. By using air suspensions to coat medical devices, the methods of the present invention result in coatings ...

LOCAL VASCULAR DELIVERY OF 2-METHOXYESTRADIOL IN COMBINATION WITH RAPAMYCIN TO PREVENT RESTENOSIS FOLLOWING VASCULAR INJURY

... ²Medical devices, and in particular implantable medical devices, may be coated ²to ²minimize or substantially eliminate a biological organism's reaction to the ²introduction of the medical device to the organism. The medical devices may be ²²coated with any number of biocompatible materials. Therapeutic drugs, agents ²or ²compounds may be mixed with the biocompatible materials and affixed to at ²least ²a portion of the medical device. in addition, various polymer combinations may ²be ²utilized to control the elution rates of the therapeutic drugs, agents and/or ²compounds from the implantable medical devices. The medical device is ²disclosed that comprises an implantable structure, a basecoat matrix and a ²topcoat. The basecoat matrix includes a combination of rapamycin and ²2- methoxyestradiol, in therapeutic dosages, incorporated in a first polymeric ²material. ²The basecoat matrix is affixed to the surface of the implantable medical ²device. ²The topcoat includes a second polymeric material ...

METHOD FOR PRODUCING IMPLANTS WITH AN ULTRAHYDROPHILIC SURFACE

The invention relates to method for producing implants with an ultrahydro philic surface and the implants produced thus, and methods for producing cha rged, so-called bioactive implant surfaces of ceramic or metallic materials of use for implants such as artificial knees, joints, tooth implants, small implants, for example, so-called stents, and implants produced according to said method, so-called 'delivery devices' which permit a controlled release, for example, by dissociation of bioactive molecules from the implant materi als.

DRUG ELUTING COMPOSITE

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

AN IMPLANTABLE MEDICAL DEVICE COMPRISING A SUBSTRATE, A COATING, AND A LAYER

An implantable medical device, which comprises a device substrate, a coating on the substrate which includes a drug which is highly soluble in water, and a protective layer which overlies the coating. The protective layer comprises a polymer selected from the group consisting of polylactic acid, polyglycolic acid and a lactic acid/glycolic acid copolymer having a weight average molecular weight of not more than 40,000.

AN IMPLANTABLE MEDICAL DEVICE

An implantable medical device, which comprises a device substrate, a coating on the substrate which includes a drug which is highly soluble in water, and a protective layer which overlies the coating. The protective layer comprises a polymer selected from the group consisting of polylactic acid, polyglycolic acid and a lactic acid/glycolic acid copolymer having a weight average molecular weight of not more than 40,000.

STENTS HAVING BIOABSORBABLE LAYERS

Provided herein is a coated coronary stent, comprising: a. stent framework; b. a plurality of layers deposited on said stent framework to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.

DRUG DELIVERY COLLAGEN SYNTHETIC VASCULAR GRAFT

A collagen-impregnated vascular graft including drug materials complexed with the collagen to be released slowly from the graft following implant. The graft is a porous synthetic vascular graft substrate having collagen fixed to the graft substrate and cross-linked in situ to render the porous substrate blood-tight. The drug materials complexed with the collagen fibrils may include antithrombic agents, antibacterial, antimicrobial agents, antifungal agents and the like.

LOCAL VASCULAR DELIVERY OF ETOPOSIDE IN COMBINATION WITH RAPAMYCIN TO PREVENT RESTENOSIS FOLLOWING VASCULAR INJURY

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable ...

MEDICAL DEVICES HAVING ANTIMICROBIAL COATINGS THEREON

The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial LbL coating containing one or more antimicrobial peptides. The antimicrobial coating of the invention can impart to the medical an increased surface hydrophilicity and a relatively high antimicrobial activity coupled with low cytotoxicity. The antimicrobial coating of the invention has a minimal adverse effects on the desirable bulk properties of a contact lens, such as oxygen permeability, ion permeability, and optical properties. An antimicrobial coating of the present invention may find particular use in extended-wear contact lenses. In addition, the invention provides a method for making a medical device, preferably a contact lens, having an antimicrobial LbL coating thereon.

THREE-DIMENSIONAL POROUS POLYURETHANE SCAFFOLD FOR REPAIRING CENTRAL NERVE INJURIES AND PREPARATION METHOD THEREOF

Disclosed are a three-dimensional porous polyurethane stent for repairing central nerve injuries and a preparation method. The stent comprises three-dimensional porous polyurethane, wherein the compression modulus of same is 0.001-10.0 MPa, and the pore size of same is 10-200 microns. The three-dimensional porous polyurethane stent has an efficient central nerve repair function without the need for additional inoculation of functional cells or factors, and can partially restore the original nerve function of tested animals; and the preparation method is simple and has great application prospects.

COMPOSITION AND METHOD FOR PREPARING BIOCOMPATIBLE SURFACES

The invention provides methods and compositions for providing biocompatible surfaces to medical articles. In particular the invention provides biocompatible coatings with heparin activity. In some aspects, the biocompatible coatings of the invention are able to release a bioactive agent. The coatings can be formed using biostable or biodegradable polymeric material and photoreactive groups. The invention also provides methods for improving the quality of bioactive agent-containing coatings by performing pre- irradiation of biocompatible coating compositions.

STENT WITH A COATING FOR DELIVERING A THERAPEUTIC AGENT

The invention relates generally to a medical device for delivering a ther apeutic agent to the body tissue of a patient, and methods for making such a medical device. More particularly, the invention is directed to a stent, su ch as an intravascular stent, having an inner and outer coating compositions disposed thereon. In another embodiment, the inner coating composition and outer coating composition are separated by a barrier coating composition. ...

DRUG DELIVERY DEVICE COMPRISING A BILAYERED POLYMERIC COATING HAVING A CELL CYCLE INHIBITOR THAT ACTS SELECTIVELY AT THE G1 PHASE OF THE CELL CYCLE INCORPORATED INTO THE FIRST POLYMER COATING LAYER

... ²²There is provided herein a drug delivery device comprising an intraluminal ²medical ²device, the intraluminal medical device including a stent having a fenestrated ²²structure, the stent comprising a plurality of bands and links defining a ²substantially ²tubular device with openings. The device further comprises a polymeric coating ²²affixed to the bands and links of the fenestrated structure, the polymeric ²coating ²having first and second layers; and a therapeutic dosage of rapamycin ²incorporated ²into the polymeric coating for treatment of intimil hyperplasia, constrictive ²vascular ²remodeling, and inflammation caused by injury. The rapamycin is incorporated ²into ²the first layer of the polymeric coating, the first layer comprising a ²solution of ²ethylene-co-vinylacetate and polybutylmethacrylate. The second layer, ²comprising ²polybutylmethacrylate, acts as a diffusion layer. The first layer has a ²thickness in the ²range from about eight microns to about twelve microns and the ...

COATINGS FOR CONTROLLED RELEASE OF HIGHLY WATER SOLUBLE DRUGS

The present disclosure relates to a multilayer coatings that include a hydrophobic encasing layer and allow controlled release of a water soluble drug. The encasing layer encases water soluble, or hydrophilic, drugs with a flexible layer and comes in good intimate contact with the water soluble drug layer. Thus, the encasing layer conforms to the water soluble drug and can control the release of the drug. Advantageously, major cuts or fissures in the coating do not cause the water soluble drug to leak or burst out; rather, the encasing layer continues to provide modulated release of the drug. The present disclosure also includes methods of making the coating, methods of using the coating, and articles that include the coating.

SILICONE-GEL-COATED ADHESIVE LAYER STRUCTURE

The invention relates to a silicone gel-coated adhesive layer structure, to a method for producing same, and to the use thereof. The layer structure comprises a porous carrier material, an intermediate layer applied to one side of the porous carrier material, and an adhesive silicone gel layer applied to the intermediate layer.

COATED DEVICES AND METHOD OF MAKING COATED DEVICES THAT REDUCE SMOOTH MUSCLE CELL PROLIFERATION AND PLATELET ACTIVITY

The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption. The present invention also provides products and methods for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition in a location within the body of ...

GRAFT MATERIALS AND METHODS FOR STAGED DELIVERY OF BIOACTIVE COMPONENTS

Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).

ANTIBACTERIAL MEDICINAL PRODUCT AND METHOD FOR PRODUCING SAME

The invention relates to a medicinal product, comprising an antibacterial hard material coating, which is applied to a main body and which comprises biocide. Said hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant and greater than the biocide concentration in the inner layer and the biocide concentration in the inner layer is greater than or equal to 0.2 at%.

MULTILAYER IMPLANTS FOR DELIVERY OF THERAPEUTIC AGENTS

Enzymatically degradable compositions containing biocompatible polymers reactive with glycosaminoglycan compositions having a first glycosaminoglycan having a first degree of acetylation and a second glycosaminoglycan having a second degree acetylation different than the first degree of acetylation.

IMPLANTABLE MEDICAL DEVICE

A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one layer 18 of a bioactive material posited on one surface of structure 12; and at least one porous layer 20 posited over the bioactive material layer 18 posited on one surface of structure (12) and the bioactive-material-free surface. Preferably, the structure 12 is a coronary stent. The porous layer 20 is comprised of a polymer applied preferably by vapor or plasma deposition and provides a controlled release of the bioactive material. It is particularly preferred that the polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, merely by condensation of a monomer vapor. The invention is also directed to the method of manufacture of the device 10, as well as a method of using it in medical treatments.

A METHOD OF PROVIDING A SUBSTRATE WITH A HYDROPHILIC COATINGAND SUBSTRATES, PARTICULARLY MEDICAL DEVICES, PROVIDED WITH SUCH COATINGS

A substrate such as a catheter or a guide wire is provided with a lubricous, hydrophilic abrasion-resistant coating by: a) coating said substrate with a first aqueous coating composition comprising an aqueous dispersion or emulsion of a polymer having organic acid functional groups and a polyfunctional crosslinking agent having functional groups being capable of reacting with organic acid groups, and drying the coating to obtain a substantially water-insoluble coating layer still including functional groups being reactive wit~ organic acid groups, and b) contacting the dried coating layer obtained in a) with a second aqueous coating composition comprising an aqueous solution or dispersion of a hydrophilic polymer having organic acid functional groups, and drying the combined coating, the hydrophilic polymer thereby becoming bonded to the polymer of the first coating composition through the crosslinking agent. The drying can be carried out at ambient (room) temperature.

ANTI-MICROBIAL COATINGS HAVING INDICATOR PROPERTIES AND WOUND DRESSINGS

Multilayer anti-microbial materials formed to produce an interference colour, and thus an indicator of anti-microbial effect, are provided. The materials include a partly reflective base layer and a partly reflective, partly transmissive top layer balanced to produce an interference colour. The top layer is formed from an anti-microbial metal with atomic disorder. Dissolution or a change in composition of the top layer on contacting an alcohol or electrolyte causes a change in optical path length so as to produce a change in the interference colour of the material. Multilayer, laminated wound dressings are also provided. The dressing includes a first and second layer, and preferably a third layer. The first and third layers are formed of perforated, non-adherent materials and most preferably carry an anti-microbial coating as above. The second layer is sandwiched between the first and third layers and is formed of an absorbent material. At least one of the layers is formed from a plastic ...

Verfahren zur Herstellung silberhaltiger Schichten auf Leichtmetallen.

DRUG-DELIVERING WITH COLLAGES COVERING AND IMPREGNATING, SYNTHETIC CONTAINER IMPLANT.

ANTIMICROBIAL COATING WITH INDICATOR PROPERTIES AND WOUND DRESSINGS

MEDICAL IMPLANTS, CONTAINING BIOCOMPATIBLE COATING

Balloon Catheter And Method Used For Covering Medical Balloon

Preparation method of traditional Chinese medicine monomer sequence slow-release osteogenesis calcium phosphate scaffold material

Process for obtaining a photographic matter on aluminium and its alloys

ACETABULUM FOR HIP PROSTHESIS

L'invention concerne un cotyle pour prothèse de hanche en un polymère biocompatible, ledit cotyle étant recouvert d'un revêtement qui comprend une première couche de titane qui a été appliquée par compression à chaud sur ledit polymère biocompatible et qui se caractérise en ce que : - la rugosité de la première couche de titane pur ou de TA6V est comprise entre 40 et 500 µm, de manière préférée entre 100 et 200 µm, et l'épaisseur est comprise entre 50 à 800 µm, de manière préférée entre 150 et 250 µm. - ledit revêtement comprend en outre sur la première couche : • une deuxième couche de titane ou d'un phosphate de calcium ; •optionnellement, sur ladite deuxième couche si cette deuxième couche est une couche de titane,une troisième couche d'un phosphate de calcium. L'invention a aussi pour objet le procédé de fabrication dudit cotyle.

SUSTAINED RELEASE DEVICE AND METHOD FOR OCULAR DELIVERY OF CARBONIC ANHYDRASE INHIBITORS

Belagd medicinsk anordning

MEDICAL IMPLANT AND METHOD FOR PRODUCING SUCH AN IMPLANT

The invention relates to a medical implant comprising a body (10), which at least in some areas is made of at least one biodegradable, crystalline material. The invention is characterized in that the body (10) comprises at least two different first and second areas (11, 12), wherein the crystalline material of the first area (11) has a different grain size than the crystalline material of the second area (12).

ANTIBACTERIAL COATING FOR AN IMPLANT AND METHOD FOR PRODUCING SAID COATING

The invention relates to the antibacterial coating for an implant, which is characterized in that the coating contains copper. The invention also relates to a method for producing an antibacterial coating for an implant, wherein the coating is applied by means of a PVD process, said method being characterized in that the layer produced contains a proportion of copper.

MEDICAL DEVICES HAVING INORGANIC BARRIER COATINGS

Medical devices having a barrier layer comprising an inorganic material. The medical device has a reservoir containing a therapeutic agent and the barrier layer is disposed over the reservoir. In one aspect, the barrier layer has one permeability to the therapeutic agent at one portion of the medical device and a different permeability at another portion of the medical device. In another aspect, the dosage amount of the therapeutic agent in the reservoir at one portion of the medical device is different from the dosage amount of the therapeutic agent in the reservoir at another portion of the medical device. In another aspect, a bioresorbable layer is disposed over the barrier layer at one or more portions of the medical device, wherein the bioresorbable layer comprises a bioresorbable material. Also, methods of coating a medical device are disclosed, in which a barrier layer over a medical device is formed using a lithographic etching process where a plurality of particles serve as an ...

MEDICAL DEVICE COATING BY LASER CLADDING

Methods for making medical devices having porous coatings. Methods may comprise providing a tubing section having inner and outer surfaces and positioning a nozzle proximate to a target surface of the parent tubing section. A powder form of the porous coating may be delivered toward the tubing section, and a laser may be directed at the powder to melt the powder to form a melt pool. The melt pool can solidify to form the porous coating on the target surface. Portions of the parent tubing section may then be cut away to form the support structure of the medical device, such as a stent.

TAPE HAVING PATTERN OF ADHESIVE LAYERS

An adhesive tape includes a base material and a plurality of adhesive layers disposed on a first side of the base material. A plurality of exposed base material areas separate the plurality of adhesive layers, such that when the adhesive tape is viewed from the first side, the plurality of exposed base material areas appear to be a plurality of intersecting lines.

MEDICAL IMPLANTS COMPRISING BIOCOMPATIBLE COATINGS

The invention relates to implantable medical devices comprising biocompatible coatings, in addition to a method for their production. The invention relates in particular to medical implantable devices that are coated with a layer containing carbon. Said devices are produced by the application of a polymer film to at least part of the device and by heating said polymer film in an atmosphere that is essentially devoid of oxygen, at temperatures ranging between 200 °C and 2500 °C, thus creating a layer containing carbon on the implantable medical device.

ANTI-MICROBIAL COATINGS HAVING INDICATOR PROPERTIES AND WOUND DRESSINGS

Multilayer anti-microbial materials formed to produce an interference colour, and thus an indicator of anti-microbial effect, are provided. The materials include a partly reflective base layer and a partly reflective, partly transmissive top layer balanced to produce an interference colour. The top layer is formed from an anti-microbial metal with atomic disorder. Dissolution or a change in composition of the top layer on contacting an alcohol or electrolyte causes a change in optical path length so as to produce a change in the interference colour of the material. Multilayer, laminated wound dressings are also provided. The dressing includes a first and second layer, and preferably a third layer. The first and third layers are formed of perforated, non-adherent materials and most preferably carry an anti-microbial coating as above. The second layer is sandwiched between the first and third layers and is formed of an absorbent material. At least one of the layers is formed from a plastic ...

COATING MEDICAL DEVICES USING AIR SUSPENSION

Cette invention a trait à des procédés et aux appareils correspondants permettant d'enrober des dispositifs médicaux ainsi qu'aux dispositifs médicaux ainsi produits. Dans un mode de réalisation, le procédé consiste à mettre le dispositif médical en suspension dans un courant d'air et à introduire un matériau d'enrobage dans ce courant d'air de sorte qu'il s'y disperse et enrobe au moins une partie du dispositif médical. Dans une autre réalisation, les dispositifs médicaux sont mis en suspension dans un courant d'air et un appareil d'enrobage enrobe au moins une partie du dispositif au moyen d'un matériau d'enrobage. L'appareil d'enrobage peut comporter un dispositif utilisant n'importe quel nombre de variantes de techniques d'enrobage pour enrober ces dispositifs médicaux. On utilise ce procédé pour appliquer un ou plusieurs matériaux d'enrobage, en même temps ou successivement. Dans certaines réalisations, les matériaux d'enrobage comportent des agents thérapeutiques, des polymères, des ...

COMPLIANT POLYMERIC COATINGS FOR INSERTABLE MEDICAL ARTICLES

Compliant coatings for insertable medical articles are provided. In some aspects, the coating includes a diene polymer-containing layer, and a second coated layer that includes another polymer. The coating can be formed by coupling the polymer of the second coated layer to the first coated layer via latent reactive groups, such as photoreactive groups. In other aspects, the insertable medical article has a coating that provides different functional features to different surfaces of the article. The medical article can have a cylindrical shape with an interior surface having a first coating, and an exterior surface with a second coating, wherein the article also includes a plurality of openings.

LOADING AND RELEASE OF WATER-INSOLUBLE DRUGS

A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coatings is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

A METHOD OF PROVIDING A SUBSTRATE WITH A BIOCOMPATIBLE COATING

Disclosed is a method of enhancing the biocompatibility of a substrate by providing the substrate with a continuous bio-active surface coating. This method includes applying to the substrate a first coating which includes an aqueous dispersion or emulsion of a polymer containing an organic acid functional group and an excess of a polyfunctional cross-linking agent which is reactive with the organic acid groups of the polymer. A continuous bio-active surface coating is then formed over the dried first coating by applying thereover a bio-active agent containing an organic acid functional group or metal salt thereof. The first and second coatings are then dried to covalently bond the organic acid functional groups of the bio-active agent to the polymer through the excess unreacted polyfunctional cross-linking agent.

Coated implantable medical device

Methods of making coated implantable medical devices are provided. The methods include positioning a first layer comprising a bioactive on at least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to provide a controlled release of the bioactive.

Method of applying drug-release coatings

The invention is directed to a method of applying drug-release coatings whereby a polymer can be dissolved in a first solvent (solvent A) to form a polymer system and a drug can be dissolved or suspended in a second solvent (solvent B) to form a drug system. The coating or layer of coating so formed comprises a substantially uniform combination of the drug and polymer. Solvent B can be the same as or different than solvent A. The coating can be applied on a stent body by separately spraying or dipping the polymer system and the drug system onto the devices. The coating can be accomplished by either applying the polymer and drug systems sequentially or simultaneously. In certain embodiments, a drug can be suspended in solvent B. In some cases, three or more systems can be utilized. For instance, a third system containing pure solvent A or B can smooth the coating surface, if the solvent of the third spraying system is compatible with the polymer matrix.

COMPLIANT COMPOSITES FOR APPLICATION OF DRUG-ELUTING COATINGS TO TISSUE SURFACES

A compliant composite for delivering a bioactive agent including a scaffolding material and a polymer coating that together can be attached to compliant tissue surfaces is disclosed, along with methods for constructing and applying these composites. In some embodiments, the composite further comprises a barrier layer for localized delivery of the bioactive agent.

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

Rapamycin 40-O-Cyclic Hydrocarbon Esters, Compositions and Methods

A new class of rapamycin 40-O-cyclic hydrocarbon esters is disclosed. The 40-O position of the rapamycin ester has the form 40-O—R, where R is C(O)—(CH 2 ) n -X, n is 0, 1 or 2, and X is a cyclic hydrocarbon having 3-8 carbons, optionally containing one or more unsaturated bonds, and one or more linear (CH 2 )) and/or cyclic (X) carbon atoms may have an OH or halide group. Also disclosed are therapeutic compositions and methods that employ the novel analogs.

BALLOON CATHETER WITH A SIROLIMUS COATED CATHETER BALLOON FOR CONTROLLED RELEASE OF SIROLIMUS

The present invention is directed to a catheter balloon of a balloon catheter comprising a coating consisting of or containing at least one fatty acid, oil or fat and sirolimus as well as to the use of these systems and compositions. Optionally a stent is crimped on such a coated catheter balloon. Further, methods for coating the inventive catheter balloons are described.

Drug eluting expandable devices

The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.

Methods for inducing macrophage conversion in a wound

One aspect of the invention provides a method of sequentially inducing macrophage conversion in a wound. The method includes: (a) administering IL-4 to induce conversion of a first population of wound macrophages in the wound to M2A macrophages; and then (b) administering IL-10, dexamethasone, or a dexamethasone analog to induce conversion of a second population of wound macrophages in the wound to M2C macrophages.

STENT COATING

Therapeutic agent delivery device with protective separating layer

An implantable medical device is disclosed, comprising: an implantable device body 10 having a plurality of through holes 20 therein; a barrier layer 66 formed in the plurality of through holes 20, the barrier layer 66 formed of a biodegradable copolymer having a copolymer ratio; a drug filled portion 60, 62 formed in the plurality of through holes 20 adjacent the barrier layer 66; and a cap layer 64 formed in the plurality of holes 20 adjacent the drug filled portion 60, 62, wherein said cap layer 64 is different from said barrier layer 66.

PROCESS AND SYSTEMS FOR BIOCOMPATIBLE SURFACES

MEDICAL DEVICES WITH DRUG-ELUTING COATING

MEDICAL DEVICE, ENDOVASCULAR STENTS, AND CATHETER FOR DRUG DELIVERY

PROBLEM TO BE SOLVED: To provide a medical device, such as a stent or balloon of a balloon catheter, which includes a body portion which has an exterior surface which contacts, at least in part, a vessel wall during treatment. SOLUTION: A body portion is expandable from a first position, wherein the body portion is sized for insertion into the vessel lumen, to a second position, wherein at least a portion of the exterior surface is in contact with the lumen wall. The medical device includes a first coating disposed over at least a portion of the exterior surface of the body portion and including a drug or therapeutic substance which is intended for controlled release from the surface. The medical device further includes a second coating overlying at least a substantial portion of the first coating. The second coating includes a material that is generally impervious to elution of the drug or therapeutic substance therethrough when the body portion is in a first position when inserted into ...

Solid dressing for treating wounded tissue

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Drug eluting implantable medical device with hemocompatible and/or prohealing topcoat

The present invention relates to implantable medical devices coated with polymer having hemocompatible and/or prohealing moieties appended thereto and to their use in the treatment of vascular diseases.

Materials for soft and hard tissue repair

Biomaterials and methods and uses for repair or augmentation of tissues are provided. In particular, the invention provides a multi-layered, naturally occurring multi-axial oriented biomaterial comprising predominately type I collagen fibers. The invention further provides methods and uses for repair or augmentation of tissues using biomaterials of the invention.

Tape having pattern of adhesive layers

An adhesive tape includes a base material and a plurality of adhesive layers disposed on a first side of the base material. A plurality of exposed base material areas separate the plurality of adhesive layers, such that when the adhesive tape is viewed from the first side, the plurality of exposed base material areas appear to be a plurality of intersecting lines.

Method for Making Medical Devices Having Antimicrobial Coatings Thereon

The present invention provides a method for preparing a medical device, preferably a contact lens, having an antimicrobial metal-containing LbL coating on a medical device, wherein the antimicrobial metal-containing LbL coating comprises at least one layer of a negatively charged polyionic material having —COOAg groups and/or silver nanoparticles formed by reducing Ag + ions associated with the —COO − groups of the negatively charged polyionic material. In addition, the present invention provides a medical device prepared according to a method of the invention.

Method of making a stent

A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.

Progesterone-containing compositions and devices

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices.

Gas based wound and tissue therapeutics

This invention provides articles of manufacture and bandages comprising compartments and layers comprising oxygen and other therapeutic gas storage forms and perfluorocarbons. This invention also provides for methods of delivering oxygen and other therapeutic gases to a tissue in a subject comprising a administering to the tissue a composition comprising a perfluorocarbon and a oxygen or therapeutic gas storage form, so as to thereby deliver oxygen or the therapeutic gas to the tissue.

Drug Eluting Implantable Medical Device With Hemocompatible And/Or Prohealing Topcoat

The present invention relates to implantable medical devices coated with polymer having hemocompatible and/or prohealing moieties appended thereto and to their use in the treatment of vascular diseases.

Solid dressing for treating wounded tissue and processes for mixing fibrinogen and thrombin while preserving fibrin-forming ability, compositions produced by these processes, and the use thereof

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

Implant for non-luminal area

A bioabsorbable implant for non-luminal region comprising: a core structure including a magnesium alloy having a predetermined shape; a first corrosion-resistant layer containing a magnesium fluoride layer as a main component formed on the core structure via fluorination of a surface of the magnesium alloy; and a second corrosion-resistant layer containing a parylene formed on the magnesium fluoride layer.

Sealant Dressing with Removable Intermediate Separating Layer

The present invention is directed to medical devices having a first porous substrate layer with at least a surface coating thereon of a first co-reactive component and a second substrate layer with at least a surface coating layer of a second co-reactive component that reacts with the first co-reactive component, and a removable barrier layer positioned between the first substrate layer and second substrate layer and in contact with said first substrate layer and said second substrate layer. 1. A medical device comprising:a. a first porous substrate layer have at least one major facing surface with at least a surface coating thereon of a first co-reactive component;b. a second substrate layer having at least one major facing surface with at least a surface coating layer of a second co-reactive component that reacts with the first co-reactive component; andc. a removable barrier layer positioned between the first substrate layer and second substrate layer and in contact with at least one major facing surface or a surface coating, each, independently of one another, from said first substrate layer and said second substrate layer.2. A medical device according to wherein the first substrate layer is a porous claim 1 , non-woven mesh constructed from one or more synthetic polymers or copolymer claim 1 , cellulosic materials claim 1 , and blends thereof.3. A medical device according to wherein the second substrate layer is a porous claim 2 , non-woven mesh constructed from one or more synthetic polymers or copolymer claim 2 , cellulosic materials claim 2 , and blends thereof.4. A medical device according to claim 1 , wherein the second substrate layer is non-porous film.5. A medical device according to claim 3 , wherein a non-porous film is applied onto a top facing surface of the second substrate layer.6. A medical device according to wherein at least one major surface of the first substrate layer is coated with a nucleophilic group-containing compound as the first co- ...

EMBOLIC MICROSPHERES

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles. 1. Injectable particles comprising at least one pH-altering agent that is configured to be released from the injectable particles in vivo upon embolization of an intratumoral artery of a tumor with the injectable particles.2. The injectable particles of claim 1 , wherein the injectable particles are configured such that claim 1 , upon embolization of the intratumoral artery of the tumor with the injectable particles claim 1 , the injectable particles release the pH-altering agent such that a microenvironment is created in a vascular bed of the tumor downstream of the injectable particles that has a pH that is higher than a pH that would otherwise exist in the absence of the pH-altering agent.3. The injectable particles of claim 1 , wherein the injectable particles are spherical or non-spherical particles.4. The injectable particles of claim 1 , wherein the injectable particles range from 20 to 1500 microns in diameter.5. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value of 7.5 or more claim 1 , (b) a buffering agent having a pKa value of 7.6 or more claim 1 , or a combination of (a) and (b).6. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value ranging from 7.5 to 10 claim 1 , (b) a buffering agent having a pKa value ranging from 8 to 35 claim 1 , or (c) a combination of (a) and (b).7. The ...

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups. 113-. (canceled)14. A medical device for delivering a therapeutic agent to a tissue , the medical device comprising a coating layer overlying an exterior surface of the medical device , the coating layer comprising a therapeutic agent and an additive , wherein:therapeutic agent is chosen from paclitaxel, rapamycin, beta-lapachone, biologically active vitamin D, and combinations thereof;the additive comprises an anionic surfactant chosen from aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, zinc stearate, sodium oleate, zinc oleate, potassium oleate, sodium stearyl fumarate, sodium lauroyl sarcosinate, or sodium myristoyl sarcosinate.15. The medical device of claim 14 , wherein the therapeutic agent is chosen from paclitaxel claim 14 , rapamycin claim 14 , and combinations thereof.16. The medical device of claim 14 , wherein the therapeutic agent comprises paclitaxel.17. The medical device of claim 14 , wherein the additive comprises aluminum stearate claim 14 , sodium stearate claim 14 , calcium stearate claim 14 , magnesium stearate claim 14 , or zinc stearate.18. The medical device of claim 14 , wherein the additive comprises magnesium ...

PEM LAYER-BY-LAYER SYSTEMS FOR COATING SUBSTRATES TO IMPROVE BIOACTIVITY AND BIOMOLECULE DELIVERY

The invention relates to polyelectrolyte multilayer coatings and, methods for their preparation and application to substrates to enhance the bioactivity and corrosion protection of the substrates' surface. The invention is particularly suitable for coating substrates employed for medical applications, such as but not limited to medical implant devices for drug and/or biologics delivery in a patient. The substrate has a positive or negative charge. The polyelectrolyte multilayer coatings include at least a first polymer layer and a second polymer layer. The first polymer and second polymer have opposite charges. Each of the polymer layers is individually applied using a layer-by-layer such that an alternating charge multilayer coating is formed. 1. A coated medical implant device , comprising:a charged substrate having a positive charge or a negative charge; and at least one polymer layer comprising a first polymer and having a positive charge; and', 'at least one polymer layer comprising a second polymer and having a negative charge;, 'a plurality of interfacing, individual polymer layers, comprising, 'a polyelectrolyte multilayer coating deposited on the charged substrate, comprisingwherein an initial polymer layer of the plurality of interfacing, individual polymer layers is deposited on the charged substrate and has a charge opposite the charged substrate, andwherein an outer polymer layer of the plurality of interfacing, individual polymer layers forms an exterior surface of the charged substrate; andan active substance deposited on the exterior surface of the charged substrate.2. The device of claim 1 , wherein the charged substrate is selected from the group comprising magnesium metal claim 1 , magnesium alloy claim 1 , iron metal claim 1 , iron alloy claim 1 , ferrous metal and ferrous alloy.3. The device of claim 1 , wherein the charged substrate is degradable.4. The device of claim 1 , wherein the charged substrate is formed by treating a neutral substrate ...

BIOLOGICAL FIBER MEMBRANE AND METHOD FOR PREPARING THE SAME

The present invention provides a biological fiber membrane formed by bacteria of the genus . The biological fiber membrane includes a first surface layer and an opposing second surface layer and a three-dimensional reticular structure bound between the first surface layer and the second surface layer, such that the moisturizing property of the biological fiber membrane is improved, thereby carrying more active ingredients. The present invention further provides a method for preparing a biological fiber membrane. 1Gluconacetobacter. A biological fiber membrane formed by culturing bacteria of the genus in a culture medium having mannitol , peptone , yeast extract and agar , comprising:a first surface layer and an opposing second surface layer; anda three-dimensional reticular structure bound between the first surface layer and the second surface layer, wherein the density of the three-dimensional reticular structure is smaller than the density of the first surface layer and the second surface layer, wherein the three-dimensional reticular structure has a plurality of backbone fibers parallel to each other and a plurality of inter-layer fibers interwoven at any two of adjacent backbone fibers, and the diameter of each of the plurality of backbone fibers is greater than or equal to the diameter of each of the plurality of inter-layer fibers, and wherein the plurality of backbone fibers extend along a longitudinal direction or a width direction of the biological fiber membrane.2. The biological fiber membrane of claim 1 , wherein the three-dimensional reticular structure is composed of a plurality of biological fibers.3. (canceled)4. The biological fiber membrane of claim 1 , wherein the plurality of backbone fibers and the plurality of inter-layer fibers are biological fibers.5. (canceled)6. The biological fiber membrane of claim 1 , further comprising an active ingredient or a drug.7. The biological fiber membrane of claim 6 , wherein the active ingredient is selected ...

COATING FOR INTRALUMINAL EXPANDABLE CATHETER PROVIDING CONTACT TRANSFER OF DRUG MICRO-RESERVOIRS

A coating for an expandable portion of a catheter comprising a hydrophobic matrix and a dispersed phase is disclosed. The dispersed phase comprises a plurality of micro-reservoirs dispersed in the hydrophobic matrix, wherein the plurality of micro-reservoirs comprises a first active agent and a first biodegradable or bioerodable polymer. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided. 1. A catheter comprising:an expandable portion on an elongated body; and a hydrophobic matrix, wherein the hydrophobic matrix comprises a cholesterol and a fatty acid; and', 'a dispersed phase comprising a plurality of micro-reservoirs dispersed in the hydrophobic matrix, wherein the plurality of micro-reservoirs comprises a first active agent and a biodegradable or bioerodable polymer; and', 'wherein the hydrophobic matrix is configured to adhere to a luminal surface when the expandable portion is expanded, and transfer at least a portion of the plurality of micro-reservoirs to the luminal surface., 'a first coating over an outer surface of the expandable portion, wherein the coating comprises2. The catheter of claim 1 , wherein the weight ratio of cholesterol to fatty acid is in the range of about 1:2 to about 3:1.3. The catheter of claim 1 , wherein the fatty acid is selected from the group consisting of lauric acid claim 1 , lauroleic acid claim 1 , tetradeadienoic acid claim 1 , octanoic acid claim 1 , myristic acid claim 1 , myristoleic acid claim 1 , decenoic acid claim 1 , decanoic acid claim 1 , hexadecenoic acid claim 1 , palmitoleic acid claim 1 , palmitic acid claim 1 , linolenic acid claim 1 , linoleic acid claim 1 , oleic acid claim 1 , vaccenic acid claim 1 , stearic acid claim 1 , eicosapentaenoic acid claim 1 , arachadonic acid claim 1 , mead acid claim 1 , arachidic acid claim 1 , docosahexaenoic acid claim 1 , ...

METHODS AND COMPOSITIONS FOR WOUND HEALING

The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polyelectrolytes to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound. 129.-. (canceled)30. A method for synthesizing a device for treatment of a wound , comprising:a) assembling alternating layers of polyelectrolytes on a polymeric support to form a nanoscale polyelectrolyte multilayer on said support;b) incubating said multilayer in bulk solution of a silver salt;c) exposing said multilayer to a reducing agent to produce zerovalent silver ions.31. The method of claim 30 , wherein at least one of said polyelectrolytes comprises a solution containing poly(allylamine hydrochloride).32. The method of claim 30 , wherein at least one of said polyelectrolytes comprises a solution containing poly(acrylic acid).33. The method of claim 30 , wherein said bulk solution of a silver salt comprises silver nitrate.34. The method of claim 30 , wherein the concentration of Ag in said silver nitrate solution is about 5 mM.35. The method of claim 32 , wherein the pH of said poly(acrylic acid) solution is about 2.5 to 7.5.36. A method for synthesizing a device for treatment of a wound claim 32 , comprising:a) assembling alternating layers of polyelectrolytes to form a nanoscale polyelectrolyte multilayer;b) incubating said multilayer in bulk solution of a silver salt;c) exposing said multilayer to a reducing agent to produce zerovalent silver ions.37. The method of claim 36 , wherein at least one of said polyelectrolytes comprises a solution containing poly(allylamine hydrochloride).38. The method of ...

Drug releasing coatings for balloon catheters

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. 1. A balloon catheter for delivering a therapeutic agent to target site in a blood vessel , the balloon catheter comprising: the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, beta-lapachone, biologically active vitamin D, and combinations thereof; and', 'the at least one first additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, PEG sorbitan palmitates, and combinations thereof; and, 'a coating layer overlying an exterior surface of a balloon, the coating layer comprising a therapeutic agent and at least one first additive, whereina biocompatible polymer.2. The balloon catheter of claim 1 , wherein the biocompatible polymer is present in an adherent layer.3. The balloon catheter of claim 2 , wherein the adherent layer is positioned between the coating layer and the exterior surface of the balloon.4. The balloon catheter of claim 1 , wherein the biocompatible polymer is selected from the group consisting of polyolefins claim 1 , polyisobutylene claim 1 , ethylene-1-olefin copolymers claim 1 , acrylic polymers claim 1 , ...

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups. 118-. (canceled)20. The medical device of claim 19 , wherein the hydrophobic therapeutic agent is paclitaxel claim 19 , rapamycin claim 19 , or a combination thereof.21. The medical device of claim 19 , wherein the drug-releasing coating layer further comprises a second additive chosen from PEG laurates claim 19 , PEG oleates claim 19 , PEG stearates claim 19 , PEG glyceryl laurates claim 19 , PEG glyceryl oleates claim 19 , PEG glyceryl stearates claim 19 , PEG sorbitan monolaurates claim 19 , PEG sorbitan monooleates claim 19 , PEG sorbitan stearates claim 19 , PEG sorbitan laurates claim 19 , PEG sorbitan oleates claim 19 , PEG sorbitan palmitates claim 19 , sorbitol claim 19 , xylitol claim 19 , 2-ethoxyethanol claim 19 , galactose claim 19 , glucose claim 19 , mannose claim 19 , xylose claim 19 , sucrose claim 19 , lactose claim 19 , maltose claim 19 , gluconolactone claim 19 , lactobionic acid claim 19 , or combinations thereof.22. The medical device of claim 19 , wherein the drug-releasing coating layer further comprises a second additive chosen from PEG-20 sorbitan monolaurate claim 19 , PEG-20 sorbitan monooleate claim 19 , sorbitol claim 19 , xylitol claim 19 , 2-ethoxyethanol claim 19 , ...

DRUG RELEASING COATINGS FOR BALLOON CATHETERS

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. 1. A balloon catheter for delivering a therapeutic agent to a blood vessel while the balloon catheter is deployed at a target site of the blood vessel , the balloon catheter comprising:an elongate member having a guide-wire lumen, an inflation lumen, a proximal end, and a distal end,an expandable balloon attached to the distal end of the elongate member and in fluidic communication with the inflation lumen;a hub attached to the proximal end, the hub having an inflation port connected to the inflation lumen and a guide-wire port connected to the guide-wire lumen; anda coating layer overlying an exterior surface of the expandable balloon, wherein:the coating layer comprises a total drug load of a hydrophobic therapeutic agent and a combination of additives comprising a first additive and a second additive;the hydrophobic therapeutic agent is one of paclitaxel, rapamycin, or combinations thereof;the first additive is one of PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan monopalmitates, PEG sorbitan monostearates, or combinations thereof; andthe second additive is one of sorbitol, sorbitan, xylitol, gluconolactone, lactobionic acid, or combinations thereof.2. The balloon catheter of claim 1 , wherein the hydrophobic therapeutic agent is paclitaxel.3. The balloon catheter of claim 1 , wherein ...

COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION

One aspect of the invention provides a method of sequentially inducing macrophage conversion in a wound. The method includes: (a) administering IL-4 to induce conversion of a first population of wound macrophages in the wound to M2A macrophages; and then (b) administering IL-10, dexamethasone, or a dexamethasone analog to induce conversion of a second population of wound macrophages in the wound to M2C macrophages. 1. A method of sequentially inducing macrophage conversion in a wound , the method comprising:(a) administering IL-4 to induce conversion of a first population of wound macrophages in the wound to M2A macrophages; and then(b) administering IL-10, dexamethasone, or a dexamethasone analog to induce conversion of a second population of wound macrophages in the wound to M2C macrophages.2. The method of claim 1 , wherein steps (a) and (b) are sequentially performed by one or more delivery systems.3. The method of claim 2 , wherein the delivery system is a composition selected from the group consisting of: a hydrocolloid composition claim 2 , a hydrogel claim 2 , a polysaccharide-based composition claim 2 , a semi-permeable polymeric adhesive film composition claim 2 , a foam composition claim 2 , a biological composition claim 2 , a polymeric scaffold claim 2 , a sequential controlled-release delivery system claim 2 , and a layer-by-layer delivery system.4. The method of claim 3 , wherein the delivery system comprises IL-4 bound to the delivery system through a binding molecule.5. The method of claim 4 , wherein the binding molecule is non-covalently bound to the delivery system.6. The method of claim 4 , wherein the IL-4 is covalently bound to an affinity molecule that interacts with the binding molecule.7. The method of claim 4 , wherein the IL-4 is released by dissociating the IL-4 from the binding molecule.8. The method of claim 3 , wherein the delivery system comprises IL-10 bound to the delivery system through a binding molecule.9. The method of claim 8 ...

DRUG ELUTING STENT AND METHOD OF USE OF THE SAME FOR ENABLING RESTORATION OF FUNCTIONAL ENDOTHELIAL CELL LAYERS

The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE. 1. A drug eluting stent , comprising:a stent framework;a drug-containing layer;a drug embedded in the drug-containing layer; anda biocompatible base layer disposed over the stent framework and supporting the drug-containing layer,wherein the drug-containing layer has an uneven coating thickness, optionally,wherein the drug-containing layer is configured to completely dissolve/between 45 days and 60 days after implantation of the drug eluting stent.2. The drug eluting stent of claim 1 , wherein the drug-containing layer is configured to release the drug within 30 days of implantation within a vessel.3. The drug eluting stent of claim 1 , wherein a thickness of the drug-containing layer on a luminal side of the stent and a thickness of the drug-containing layer on a lateral side of the stent is less than a thickness of the drug-containing layer on an abluminal side of the stent.4. The drug eluting stent of claim 3 , where a ratio between the thickness of the drug-containing layer on the luminal side and the thickness of the drug-containing layer on the ...

Coating of a Vascular Endoprosthesis

The invention relates to a method for coating a vascular endoprosthesis, wherein the outside of the vascular endoprosthesis is wetted at least partially with a first solution of an active substance, the vascular endoprosthesis is moved in a rotational movement about the longitudinal axis of the vascular endoprosthesis, and a radially acting mechanical force is applied to the outside of the vascular endoprosthesis. The rotational movement has the effect that the solution is carried outward by the centrifugal force, such that no active substance deposits in the interior of the vascular endoprosthesis. The application of a mechanical force to the outside of the vascular endoprosthesis then has the effect of creating crystallization nuclei, such that the active substance can crystallize out.

Coatings for Controlled Release of Highly Water Soluble Drugs

The present disclosure relates to a multilayer coatings that include a hydrophobic encasing layer and allow controlled release of a water soluble drug. The encasing layer encases water soluble, or hydrophilic, drugs with a flexible layer and comes in good intimate contact with the water soluble drug layer. Thus, the encasing layer conforms to the water soluble drug and can control the release of the drug. Advantageously, major cuts or fissures in the coating do not cause the water soluble drug to leak or burst out; rather, the encasing layer continues to provide modulated release of the drug. The present disclosure also includes methods of making the coating, methods of using the coating, and articles that include the coating. 137-. (canceled)38. A drug eluting article comprising:a substrate;a water soluble drug layer comprising a freely water soluble drug, a highly water soluble drug, or a combination thereof, disposed on the substrate; anda hydrophobic encasing layer disposed on the water soluble drug layer, the hydrophobic encasing layer comprising polyisobutylene, a polymer that is a polymaleic acid derivative, a polystyrene block copolymer, a polystyrene block polyolefin copolymer, or a mixture of two or more of these,wherein drug is not mixed with binder material within the water soluble drug layer.39. The drug eluting article according to wherein the substrate comprises silicone.40. The drug eluting article according to wherein the drug eluting article is a urological device.41. The drug eluting article according to wherein the drug eluting article is a nonimplanted device.4238. The drug eluting article according to wherein the ratio of hydrophobic encasing layer to highly water soluble drug is 0.7 to 1.43. The drug eluting article according to wherein the encasing layer is present in at least a substantially equal weight amount as the highly water soluble drug.44. The drug eluting article according to wherein the ratio of hydrophobic encasing layer to highly ...

Sealant Dressing with Protected Reactive Components

The present invention is directed to multi-layered wound dressings having a carrier layer, at least two sublayers, wherein each sublayer contains at least one reactive, cross-linkable component and the at least two reactive, cross-linkable components are co-reactive with the other and at least one reactive, cross-linkable has a protective leaving group and a buffering salt agent.

MULTI-LAYER OSTEOINDUCTIVE, OSTEOGENIC, AND OSTEOCONDUCTIVE CARRIER

A spinal stabilization system for use in a vertebral column of a patient, comprising: a multi-layer osteogenic carrier device comprising: a delivery layer comprising a porous material and an osteogenic material; and a support layer in communication with the delivery layer, the support layer capable of substantially conforming to an anatomical feature in the vertebral column of the patient, wherein the support layer holds the delivery layer in proximity to the anatomical feature; at least one rod; at least one rod clip; and at least one fastener are disclosed. The multi-layer osteogenic carrier device can further comprise an adhesive layer capable of adhering the carrier to at least a portion of an anatomical feature, the adhesive layer in communication with at least a portion of the delivery layer. 1. A spinal stabilization system for use in a vertebral column of a patient , comprising: a delivery layer comprising a porous material and an osteogenic material; and', 'a support layer in communication with the delivery layer, the support layer capable of substantially conforming to an anatomical feature in the vertebral column of the patient,', 'wherein the support layer holds the delivery layer in proximity to the anatomical feature;, 'a multi-layer osteogenic carrier device comprisingat least one rod;at least one rod clip; andat least one fastener.2. The spinal stabilization system of claim 1 , wherein the rod clip comprises a first leg and a second leg.3. The spinal stabilization system of claim 2 , wherein the first and second legs are adapted to attach to the rod.4. The spinal stabilization system of claim 3 , wherein the rod clip further comprises an arm connected to the first and second legs by a stem.5. The spinal stabilization system of claim 4 , wherein the arm of the rod clip is positioned to apply pressure to the support layer of the multi-layer osteogenic carrier device to hold the multi-layer osteogenic carrier device in proximity to the anatomical ...

COATING FOR INTRALUMINAL EXPANDABLE CATHETER PROVIDING CONTACT TRANSFER OF DRUG MICRO-RESERVOIRS

A coating for an expandable portion of a catheter comprising a lipophilic matrix and a plurality of micro-reservoirs dispersed in the lipophilic matrix is disclosed. The plurality of micro-reservoirs comprises an active agent. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided. 1. A catheter comprising:an expandable portion on an elongated body; and a lipophilic matrix, wherein the lipophilic matrix comprises at least one lipid;', 'a plurality of micro-reservoirs dispersed in the lipophilic matrix, wherein the plurality of micro-reservoirs comprises an active agent; and', 'wherein the lipophilic matrix is configured to adhere to a luminal surface when the expandable portion is expanded, and transfer at least a portion of the plurality of micro-reservoirs to the luminal surface., 'a coating over an outer surface of the expandable portion, wherein the coating comprises2. The catheter of claim 1 , wherein the active agent is crystalline.3. The catheter of claim 1 , wherein the plurality of micro-reservoirs further comprises a biodegradable or bioerodable polymer.4. The catheter of claim 3 , wherein the biodegradable or bioerodable polymer is selected from the group consisting of polylactic acid claim 3 , polyglycolic acid and their copolymers claim 3 , polydioxanone claim 3 , polycaprolactone claim 3 , polyphosphazine claim 3 , collagen claim 3 , gelatin claim 3 , chitosan claim 3 , and glycosoaminoglycans.5. The catheter of claim 3 , wherein the active agent is about 10% to about 50% by weight of the micro-reservoirs.6. The catheter of claim 1 , wherein the at least one lipid comprises phospholipid.7. The catheter of claim 6 , wherein the phospholipid comprises an acyl chain length of about 20 to about 34 carbons.8. The catheter of claim 6 , wherein the phospholipid is selected from the group consisting of phosphatidylcholine ...

ANTI-THROMBOGENIC GRAFTS

The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof. 1. A composition comprising a substrate having at least one surface coated with an anti-thrombogenic coating.2. The composition of claim 1 , wherein the anti-thrombogenic coating comprises a first layer comprising a hydrogel.3. The composition of claim 2 , wherein the first layer comprises hyaluronic acid.4. The composition of claim 3 , wherein the hyaluronic acid is thiol-modified hyaluronic acid.5. The composition of claim 2 , wherein the first layer is crosslinked to the at least one surface of the substrate.6. The composition of claim 2 , wherein the anti-thrombogenic coating further comprises a second layer comprising an anti-coagulant claim 2 , wherein the second layer is crosslinked to the first layer.7. The composition of claim 6 , wherein the second layer comprises heparin.8. The composition of claim 1 , wherein the substrate is decellularized tissue.9. The composition of claim 8 , wherein the decellularized tissue is a decellularized blood vessel having a luminal surface claim 8 , and wherein the anti-thrombogenic coating is coated on the luminal surface of the decellularized blood vessel.10. A method of preparing a graft coated with an anti-thrombogenic coating claim 8 , comprising the steps of:providing a substrate having at least one surface; and applying a first crosslinking solution to the surface; and', 'applying a hydrogel solution to the surface, thereby providing a first layer on the surface of the substrate., 'coating the at least one surface with an anti-thrombogenic coating, wherein said step of coating comprises11. The method ...

IMPLANTABLE CHEMICAL SENSOR WITH STAGED ACTIVATION

Embodiments herein include implantable medical devices including chemical sensors with bioerodible masking layers to allow for staged activation of the sensors. In an embodiment, an implantable medical device includes a substrate defining wells and a first chemical sensor and a second chemical sensor disposed within separate wells of the substrate. The first chemical sensor and the second chemical sensor can be configured to detect one or more analytes. The device can include a first bioerodible masking layer disposed over the second chemical sensor, sealing off the second chemical sensor. The device can further include a protective planarization layer disposed over at least one of the first chemical sensor and the second chemical sensor such that the outermost surface of the medical device over the first sensor is flush with the outermost surface of the medical device over the second sensor. Other embodiments are also included herein. 1. An implantable medical device comprising:a substrate defining wells;a first chemical sensor and a second chemical sensor disposed within separate wells of the substrate; the first chemical sensor and the second chemical sensor configured to detect one or more analytes; 'a first material having a first erosion rate; and', 'a first bioerodible masking layer disposed over the second chemical sensor and sealing off the second chemical sensor, the first bioerodible masking layer comprising'} 'a second material having an erosion rate that is faster than the erosion rate of the first bioerodible masking layer.', 'a protective planarization layer disposed over at least one of the first chemical sensor and the second chemical sensor such that the outermost surface of the medical device over the first sensor is flush with the outermost surface of the medical device over the second sensor; the planarization layer comprising'}2. The implantable medical device of claim 1 , each of the first chemical sensor and second chemical sensor comprising ...

IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITUS

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. 124-. (canceled)25. A method of treatment of a human patient , comprising: i) a first layer comprising mometasone furoate and a biodegradable polymer material and', 'ii) a therapeutic-agent-free polymer topcoat layer, said topcoat layer positioned on said first layer; and, 'a) providing a scaffold comprising'}b) delivering said scaffold to the middle meatus under conditions where the scaffold delivers said mometasone furoate from the middle meatus to a sinus cavity of a human patient, said sinus cavity selected from the group consisting of the maxillary, frontal, sphenoid and ethmoid sinuses.26. The method of claim 25 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.27. The method of claim 25 , wherein said patient has failed medical management based on the administration of oral steroids.28. The method of claim 25 , wherein said patient has failed medical management based on the administration of topical steroids.29. The method of claim 25 , wherein said treatment is a postoperative treatment following functional endoscopic sinus surgery.30. A method of treatment of a subject with a sinus condition claim 25 , comprising: i) a first layer comprising mometasone furoate and a polymer material and', 'ii) a polymer topcoat layer, said topcoat layer positioned on said first layer; and, 'a) providing a scaffold comprisingb) delivering said scaffold to the middle meatus under conditions where the scaffold delivers said mometasone furoate from the middle meatus to a sinus cavity of a subject with a sinus condition, said sinus cavity selected from the group consisting of the maxillary, frontal, sphenoid and ethmoid sinuses.31. The method of claim 30 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.32. The method of claim 30 , wherein said subject is a human patient that has failed medical ...

SURFACE MODIFICATION METHOD AND STRUCTURE FOR IMPROVING HEMOCOMPATIBILITY OF BIOMEDICAL METALLIC SUBSTRATES

The present invention relates to a surface modification method for improving the hemocompatibility of biomedical metallic substrate, comprising: fixing a sulfur-containing monomolecular film on the surface of oxide layer of a biomedical metallic substrate by molecular self-assembly. The surface modification will improve the hydrophilicity and hemocompatibility of the biomedical metallic substrate in contact with the blood, and ensure that the biomedical metallic substrate is non-toxic to the endothelial cells. 1. A surface modified structure of biomedical metallic substrate for improving hemocompatibility , comprising:a silanol-oxide layer formed on a surface of a biomedical metallic substrate, anda sulfur-containing monomolecular film with exposed sulfur-containing functional groups formed on the surface of the silanol-oxide layer.2. The surface modification structure of claim 1 , further comprising a nitric oxide (NO) layer formed on the surface of the sulfur-containing monomolecular film.3. A method for preparing the surface modified structure of claim 1 , comprising:contacting a biomedical metallic substrate having an oxide layer with a solution of a silanol chemical derivative containing mercapto group or sulfur atom for a predetermined period of time to form a silanol-oxide layer on the biomedical metallic substrate, and a sulfur-containing monomolecular film exposing sulfur-containing functional groups on outermost surface of the silanol-oxide layer by means of molecular self-assembly.4. The method of claim 3 , wherein the predetermined period of time is 10 minutes to 24 hours.5. The method of claim 3 , wherein the silanol chemical derivative is 3-mercaptopropyltrimethoxysilane (MPTMS).6. The method of claim 3 , wherein the solution of silanol chemical derivative has a volume concentration of 0.1%˜20%.7. The method of claim 3 , further comprising a step of forming a nitric oxide (NO) layer on the surface of the sulfur-containing monomolecular film.8. A ...

Degradeable ostial stent

A polymeric stent having a length, an outer surface and a cross-section. A lumen passes through the entire length, the lumen having a surface forming an equivalent diameter in the polymeric stent. The polymeric stent includes a first aqueous-swellable, biocompatible and biodegradable composition (e.g., polymer) having a thickness. The aqueous-swellable and biodegradable polymer retaining structural integrity for at least 1 hours up to thirty days when swollen and kept moist by a moist aqueous environment. Barrier layers of biodegradable polymer(s) may be used to prevent migration of liquids into the lumen.

DRUG ELUTING COMPOSITE

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials. 1. A therapeutic-releasing device comprising: a first coated film;', 'a first therapeutic agent incorporated within the first coated film;', 'a first capping layer that substantially covers all of the first coated film and is impermeable to the first therapeutic agent; and', 'a first opening in the first capping layer; and, 'a first therapeutic-releasing construction including a second coated film;', 'a second therapeutic agent incorporated within the second coated film;', 'a second capping layer that substantially covers all of the second coated film and is impermeable to the second therapeutic agent; and', 'a second opening in the second capping layer,, 'a second therapeutic-releasing construction includingwherein the first therapeutic-releasing construction is stacked inside the second therapeutic-releasing construction.2. The therapeutic-releasing device of claim 1 , wherein the first therapeutic-releasing construction further includes a first elution pathway for the first therapeutic agent through the first coated film that exits the first coated film at the first opening.3. The therapeutic-releasing device of claim 2 , wherein the second therapeutic-releasing construction further includes a second elution pathway for the second therapeutic agent through the second coated film that exits the second coated film at the second opening.4. The therapeutic-releasing device of claim 3 , wherein the first coated film is a polymeric material comprising one or more polymeric barriers that are substantially impermeable to the first therapeutic agent and define the first elution pathway.5. The therapeutic-releasing device of claim 4 , wherein the second coated film is a polymeric material comprising ...

METHODS AND SUBSTRATES FOR DIFFERENTIATION OF NEURAL STEM CELLS

The present invention is directed to methods and substrates for promoting the differentiation of neural stem cells to neurons. 1. A substrate having one or more extracellular matrix proteins disposed thereon in a regular two-dimensional geometric pattern , wherein the proteins in the pattern have an average height dimension of from about 50 nm to about 200 nm.2. The substrate of wherein the one or more extracellular matrix proteins comprise one or more of laminin claim 1 , fibronectin and collagen.3. The substrate of wherein the extracellular matrix protein is laminin.4. The substrate of wherein the pattern is selected from stripes claim 1 , squares claim 1 , lines claim 1 , squares connected by lines claim 1 , circles connected by lines claim 1 , and a grid.5. The substrate of wherein the substrate is biocompatible.6. The substrate of wherein the substrate comprises polyimide7. The substrate of wherein the substrate has at least one neural stem cell (NSC) in contact therewith.8. The method of wherein the NSC is a human NSC.9. The substrate of claim 1 , wherein the geometric pattern is provided by a carbon nanotube monolayer.10. A method for promoting the differentiation of NSCs to neurons comprising contacting NSCs with a substrate having one or more extracellular matrix proteins disposed in a regular two-dimensional geometric pattern claim 1 , wherein the proteins in the pattern have a height dimension of from about 1 μm to about 50 μm.11. A biocompatible implant comprising a substrate having one or more extracellular matrix proteins disposed thereon in a regular two-dimensional geometric pattern claim 1 , wherein the proteins in the pattern have a height dimension of from about 1 μm to about 50 μm.12. The implant of further comprising at least one NSC.13. The implant of wherein the implant is a scaffold claim 11 , matrix or tube.14. A method of treating or ameliorating a neurodegenerative disorder or a neurological injury comprising administering the ...

Rapamycin 40-O-Cyclic Hydrocarbon Esters, Compositions and Methods

A new class of rapamycin 40-O-cyclic hydrocarbon esters is disclosed. The 40-O position of the rapamycin ester has the form 40-O—R, where R is C(O)—(CH 2 ) n —X, n is 0, 1 or 2, and X is a cyclic hydrocarbon having 3-8 carbons, optionally containing one or more unsaturated bonds, and one or more linear (CH 2 ) n ) and/or cyclic (X) carbon atoms may have an OH or halide group. Also disclosed are therapeutic compositions and methods that employ the novel analogs.

Self Assembled Films for Protein and Drug Delivery Applications

Provided are systems for controlled release of proteins from decomposable thin films constructed by layer-by-layer deposition. Such films generally comprise alternating layers of polymers and proteins, and may further comprise additional layers of polyions. In some embodiments, decomposable thin films and methods of using such films allow proteins to be released over an extended period of time and/or retention of as much as 100% of function of released protein. 1. A decomposable thin film comprising at least one tetralayer unit , the tetralayer unit comprising:a degradable polyelectrolyte layer having a first electrostatic charge;a first polysaccharide layer disposed next to the degradable polyelectrolyte layer, the polysaccharide layer having a second electrostatic charge, the first and second electrostatic charges being opposite;a carrier layer disposed next to the first polysaccharide layer, the carrier layer including at least one growth factor; anda second polysaccharide layer disposed next to the carrier layer.2. The decomposable thin film of claim 1 , wherein the at least one growth factor is a vascular endothelial growth factor (VEGF) claim 1 , a bone morphogenic protein 2 (BMP-2) claim 1 , a bone morphogenic protein 4 (BMP-4) claim 1 , or a basic fibroblast growth factor (bFGF).3. The decomposable thin film of claim 1 , wherein the degradable polyelectrolyte is a hydrolysable polyelectrolyte.4. The decomposable thin film of claim 1 , wherein the carrier layer has a third electrostatic charge and the second polysaccharide layer has a fourth electrostatic charge claim 1 , and wherein the first claim 1 , the second claim 1 , the third claim 1 , and the fourth electrostatic charges are alternating anionic and cationic charges.5. The decomposable thin film of claim 1 , wherein the carrier layer consists of a protein.6. The decomposable thin film of claim 1 , wherein the degradable polyelectrolyte layer includes a polyelectrolyte selected from the group ...

Multi-layer biomaterial for tissue regeneration and wound healing

The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.

Bioartificial pancreas

A bioartificial device, such as a bioartificial pancreas, for implantation in a patient's vascular system. The bioartificial pancreas includes a scaffold adapted to engage an interior wall of a blood vessel, a cellular complex support by the scaffold and extending longitudinally within the interior cavity of the scaffold so as to be exposed to the blood flow when the scaffold is engaged with the blood vessel, the cellular complex support comprising one or more pockets bordered by thin film; and cellular complex comprising pancreatic islets disposed in the one or more pockets, the thin film being adapted to permit oxygen and glucose to diffuse from flowing blood into the one or more pockets at a rate sufficient to support the viability of the islets. The invention also includes methods of making and using a bioartificial pancreas.

STENTS HAVING CONTROLLED ELUTION

Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form. 1. A device comprisinga. a stent; andb. a coating on the stent comprising a first layer comprising at least one bioabsorbable polymer; a second layer comprising at least one active agent; and an outer layer comprising at least one bioabsorbable polymer; wherein each of said bioabsorbable polymer layers comprises a separately sintered bioabsorbable polymer layer;wherein said outer layer comprising said at least one bioabsorbable polymer is sufficiently thin so that the active agent is present in crystalline form on at least one region of an outer surface of the coating opposite the stent and wherein 50% or less of the total amount of active agent in the coating is released after 24 hours in vitro elution.2. The device of claim 1 , wherein in vitro elution is carried out in a 1:1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37° C.; wherein the amount of active agent released is determined by measuring UV absorption.3. The device of wherein UV absorption is detected at 278 nm by a diode array spectrometer.4. The device of claim 1 , wherein between 25% and 45% of the total amount of active agent in the coating is released after 24 hours in vitro elution in a 1:1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37° C.; wherein the amount of the active agent released is determined by measuring UV absorption at 278 nm by a diode array spectrometer.5. The device of claim 1 , wherein the active agent is at least 50% crystalline.6. The device of claim 1 , wherein the active agent is at least 90% crystalline.7. The device of claim 1 , wherein the polymer comprises a PLGA copolymer.8. The device of claim 1 , wherein the ...

Crystallization Inhibitor Compositions for Implantable Urological Devices

Inventive concepts relate generally to the field of implantable urological devices, and more particularly to compositions that inhibit crystallization of urine components. Described are implantable urological devices including a surface and a crystallization inhibitor composition, the crystallization inhibitor composition including: (a) an inhibitor of urine component crystallization in combination with a biodegradable polymer, or a polyalkene homopolymer or copolymer, or (b) a biodegradable polymer that includes an inhibitor of urine component crystallization, wherein the crystallization inhibitor composition provides controlled release of the inhibitor of urine component crystallization from the surface of the device into a subject. Methods of making the implantable urological devices are also described. 1. An implantable urological device comprising a surface and a crystallization inhibitor composition , the crystallization inhibitor composition comprising:(a) an inhibitor of urine component crystallization in combination with, or included in, a biodegradable polymer, or(b) an inhibitor of urine component crystallization and a hydrophobic polymer,wherein the crystallization inhibitor composition provides controlled release of the inhibitor of urine component crystallization from the surface of the device into a subject.2. The implantable urological device of wherein the inhibitor of urine component crystallization comprises citric acid claim 1 , osteopontin or a combination of citric acid and osteopontin.3. The implantable urological device of wherein the inhibitor of urine component crystallization comprises an inhibitor of calcium salt or magnesium salt formation.4. The implantable urological device of wherein the crystallization inhibitor composition comprises a coating on the surface of the device.5. The implantable urological device of wherein the biodegradable polymer comprises a biodegradable polyester.6. The implantable urological device of wherein the ...

Coatings containing multiple drugs

A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.

Dry Absorbent Layer System

The present invention relates to absorbent articles for solving the problem of stopping the excessive accumulations of sweat from building up inside a prosthetic liner. The four layers of materials include: a first layer of a cellulose pulp material having a thickness use for a desired absorbency, a second layer of a wicking cloth material having a thickness use for a desired absorbency, a third layer of a non-toxic double side adhesive tape material one side will stick to both layer, and a fourth layer that is the opposite side which are cover with paper material that can be peeled from the third layer to adhere the inside of a prosthetic liner base sheet to stop the excessive accumulation build-up of sweating. 1. A dry absorbent layer system for use with a prosthetic liner positioned about an amputated limb , the dry absorbent layer system comprising:an absorbent material layer including a cellulose pulp material;a wicking material layer including a wicking cloth material, wherein a diameter of the wicking material layer is less than a diameter of the absorbent material layer; andan adhesive material layer including a non-toxic, double-sided adhesive material having a diameter greater than the diameter of the wicking material layer;wherein the wicking material layer is positioned between the absorbent material layer and the adhesive material layer;wherein a first side of the adhesive material layer is adhered to an outer perimeter of the absorbent material layer to form the dry absorbent system;wherein a second side of the adhesive material layer is configured to adhere to the prosthetic liner.2. The system of claim 1 , wherein the absorbent material layer includes cellulose wood pulp material.3. The system of claim 1 , wherein the absorbent material layer has a diameter between claim 1 , and including claim 1 , 3 to 5 inches.4. The system of claim 1 , wherein the wicking material layer has a diameter between claim 1 , and including claim 1 , 2.5 to 4.5 inches.5. ...

Substrate Mediated Enzymes Prodrug Therapy

A method is provided for administering an active drug agent to cells adhering and/or adjacent to a substrate, said substrate comprising one or more immobilized enzymes, which are capable of converting an inert prodrug into an active drug agent, said method comprising providing at least one inactive prodrug to said substrate. Also a kit is provided which comprise a substrate comprising one or more immobilized enzymes capable of converting an inert prodrug into an active drug agent, and at least one inert prodrug. A stent is also provided, which comprise a substrate comprising one or more immobilized enzymes capable of converting an inert prodrug into an active drug agent. 1. A method of administering at least one active drug agent to cells adhering and/or adjacent to a substrate , said substrate comprising one or more immobilized enzymes , which are capable of converting an inert prodrug into an active drug agent , said method comprising providing at least one inactive prodrug to said substrate.2. (canceled)3. A method of treating a disease in an individual , said method comprising localizing a substrate comprising one or more immobilized enzymes capable of converting an inert prodrug into an active drug agent to a target site for treatment , and systemically administering an efficient amount of at least one said inert prodrug to said individual , thereby bringing said at least one prodrug into contact with said one or more enzymes and thereby converting said inert at least one prodrug into active drug at the target site for treatment.4. The method according to claim 3 , wherein said disease is atherosclerosis and said method comprises inserting a vascular stent claim 3 , such as vascular graft claim 3 , comprising a substrate comprising one or more immobilized enzymes capable of converting an inert prodrug into an active drug agent claim 3 , into a blood vessel claim 3 , and administering at least one inert prodrug claim 3 , which is converted into active anti- ...

DRUG-ELUTING DEVICE FOR PROPHYLAXIS OR TREATMENT OF A DISEASE OR PATHOLOGY

The invention disclosed herein generally relates to particular intravascular drug-eluting delivery devices and methods for manufacture and use in either the prophylaxis or treatment of a disease or pathology. In one aspect, the drug eluting prosthesis is implanted into a patient's blood vessel upstream of a disease site. 1. A therapeutic method , for the remedial or prophylactic treatment of a disease , the method comprising: a prosthesis body having an inner surface and an outer surface;', 'at least one layer of biodegradable polymeric material bonded to at least one surface of the prosthesis body, the polymeric material being capable of absorbing and releasing one or more drugs; and', 'at least one drug dispersed within at least one layer of the polymeric material;, "implanting a drug eluting prosthesis into a patient's blood vessel upstream of a disease site, the drug eluting prosthesis comprising:"}avoiding the critical blood vessel branches at the disease site; andreleasing a drug to match the clinical manifestations.2. The method of claim 1 , wherein the prosthesis is a drug eluting stent or scaffold having a lumen and capable of radial expansion claim 1 , the prosthesis body formed from a material comprising metals claim 1 , ceramics claim 1 , polymers claim 1 , or combinations thereof.3. The method of claim 2 , wherein the material forming the prosthesis body is at least partially biodegradable.4. The method of claim 3 , wherein the material comprises nitinol.5. The method of claim 3 , wherein at least a first drug is contained within a polymeric base layer bonded to at least one surface of the prosthesis body.6. The method of claim 5 , comprising a second polymeric layer that does not comprise a drug claim 5 , the second polymeric layer built upon the base layer claim 5 , and permitting the initiation of drug release from the base layer to be delayed.7. The method of claim 5 , comprising a second polymeric layer that comprises at least one drug claim 5 , ...

TEXTILE PART

A textile part, in particular a textile orthopedic aid, including a textile main panel as well as at least one functional element from plastics material which is disposed on the main panel, wherein the functional element is connected either in a form-fitting or a form-fitting and materially integral manner to at least one fastening element, and the fastening element is connected in a materially integral manner to the main panel. 1. A textile part , in particular a textile orthopedic aid , comprising a textile main panel as well as at least one functional element from plastics material which is disposed on the main panel , wherein the functional element is connected either in a form-fitting or a form-fitting and materially integral manner to at least one fastening element , and the fastening element is connected in a materially integral manner to the main panel.2. The textile part according to claim 1 , wherein the fastening element is flexible or rigid.3. The textile part according to claim 1 , wherein the fastening element is a plastics-material element or has a carrier having a plastics-material coating on one side or both sides claim 1 , or in that a fused intermediate tier which establishes the materially integral connection is provided between the fastening element and the main panel.4. The textile part according to claim 1 , wherein the functional element and/or the fastening element or the plastics-material coating or the intermediate tier are/is composed of polyamide claim 1 , polyvinylchloride claim 1 , polyurethane claim 1 , polyethylene claim 1 , or a thermoplastic elastomer claim 1 , in particular a urethane-based thermoplastic elastomer.5. The textile part according to claim 1 , wherein a plurality of functional elements are disposed either in a form-fitting or a form-fitting and materially integral manner on a common fastening element.6. The textile part according to claim 1 , wherein a functional element which is composed of a plurality of parts that ...

DRUG RELEASING COATINGS FOR BALLOON CATHETERS

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. 2. The balloon catheter of claim 1 , wherein the hydrophobic therapeutic agent is paclitaxel.3. The balloon catheter of claim 1 , wherein the hydrophobic therapeutic agent is rapamycin.4. The balloon catheter of claim 1 , wherein the hydrophobic therapeutic agent is a combination of antioxidants and paclitaxel or rapamycin.5. The balloon catheter of claim 1 , wherein the total drug load of the hydrophobic therapeutic agent is from 1 μg to 20 μg per square millimeter of the expandable balloon.6. The balloon catheter of claim 1 , wherein the total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon.7. The balloon catheter of claim 1 , wherein the first additive is a PEG sorbitan monolaurate.8. The balloon catheter of claim 7 , wherein the PEG sorbitan monolaurate is PEG-20 sorbitan monolaurate.9. The balloon catheter of claim 1 , wherein the first additive is a PEG sorbitan monooleate.10. The balloon catheter of claim 9 , wherein the PEG sorbitan monooleate is PEG-20 sorbitan monooleate.11. The balloon catheter of claim 1 , wherein the first additive is one of PEG-20 sorbitan monolaurate claim 1 , PEG-20 sorbitan monooleate claim 1 , or combinations thereof.12. The balloon catheter of claim 1 , wherein the second additive is one of sorbitol claim ...

MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF

A metal-organic compound containing polymer matrix includes a polymer and a three-dimensional metal-organic framework includes a polydentate organic linker. The metal-organic compound containing polymer matrix is configured to continuously produce nitric oxide when exposed to a physiological fluid including a nitric oxide-releasing compound via a catalytic reaction catalyzed by the three-dimensional metal-organic framework. 2. The method of wherein X claim 1 , Xand Xare triazolyls.3. The method of wherein X claim 1 , Xand Xare tetrazoyls.4. The method of wherein X claim 1 , Xand Xare COH.5. The method of claim 1 , wherein the metal-organic framework has a porous structure comprising pores having an average size of about 5 Å to about 500 Å in diameter.6. The method of claim 1 , wherein the nitric oxide-releasing compound comprises a functional group selected from the group consisting of S-nitrosothiol claim 1 , diazeniumdiolate claim 1 , nitrate claim 1 , nitrite claim 1 , nitroso claim 1 , and nitrosyl.7. The method of claim 1 , wherein the polymer is selected from the group consisting of poly(ε-caprolactone) and polyglycolide and mixtures and copolymers thereof.8. The method of claim 1 , wherein the polymer is selected from the group consisting of polyurethane (PU) claim 1 , polyesters claim 1 , polyethers claim 1 , silicones claim 1 , silicates claim 1 , poly(vinyl chloride) (PVC) claim 1 , acrylates claim 1 , methacrylates claim 1 , dextran claim 1 , synthetic rubber (cis-polyisoprene) claim 1 , polyvinyl acetate claim 1 , Bakelite claim 1 , polychloroprene (neoprene) claim 1 , nylon claim 1 , polystyrene claim 1 , polyethylene claim 1 , polypropylene claim 1 , polyacrylonitrile claim 1 , polyvinyl butyral (PVB) claim 1 , poly(vinylidene chloride) claim 1 , fluorinated polymers claim 1 , polytetrafluoroethylene (PTFE) claim 1 , poly(ε-caprolactone) claim 1 , polyglycolide and mixtures and copolymers thereof.10. The metal-organic compound containing polymer matrix ...

Delivery of hydrophobic active agent particles

Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein.

DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES

Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein. 1. A drug delivery coating comprisinga base polymeric layer, the base polymeric layer comprising a hydrophilic surface; a particulate hydrophobic therapeutic agent; and', 'a cationic block copolymer comprising charged blocks and uncharged blocks., 'a therapeutic agent layer forming an exterior surface the drug delivery coating, the therapeutic agent layer contacting the hydrophilic surface of the base polymeric layer and having a composition different than the base polymeric layer, the therapeutic agent layer comprising'}2. The drug delivery coating of claim 1 , the cationic block copolymer comprising a PLGA block.3. The drug delivery coating of claim 1 , the cationic block copolymer comprising a PEG block.4. The drug delivery coating of claim 1 , the cationic block copolymer selected from the group consisting of PEG-PEI and PLGA-PEI.5. The drug delivery coating of claim 1 , the base polymeric layer further comprising a photo-crosslinker comprising at least two aryl ketone functionalities.7. The drug delivery coating of claim 1 , wherein the base polymeric layer comprises a hydrophilic polymer having pendent photoreactive groups.8. The drug delivery coating of claim 7 , the hydrophilic polymer having pendent photoreactive groups comprising a photo-polyacrylamide.9. The drug delivery coating of claim 8 , wherein the photo-polyacrylamide is chosen from ...

Coatings Containing Multiple Drugs

A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents. 1. A pharmaceutical product comprising:a. a core,b. a coating deposited on said core, said coating comprising at least one pharmaceutical layer comprising a pharmaceutical agent having a morphology that is crystalline or semi-crystalline, andc. at least one polymer layer in dry powder form deposited on said at least one pharmaceutical layer, said at least one polymer layer being sufficiently thin such that at least a portion of said at least pharmaceutical layer is at the surface of said coating.2. The pharmaceutical product of claim 1 , wherein said at least one polymer layer comprises a bioabsorbable polymer.3. The pharmaceutical product of claim 1 , wherein said at least one polymer layer comprises a sintered layer in which the morphology of said pharmaceutical agent in said coating has not been substantially modified.4. The pharmaceutical product of claim 1 , wherein said polymer of said at least one polymer layer is selected from PLA claim 1 , PLGA claim 1 , PGA claim 1 , and Poly(dioxanone).5. The pharmaceutical product of claim 1 , wherein said coating comprises five or more layers claim 1 , as follows:a first polymer layer;a first pharmaceutical layer comprising said at least one pharmaceutical layer;a second polymer layer;a second pharmaceutical layer comprising said at least one pharmaceutical layer comprising a pharmaceutical agent having a morphology that is crystalline or semi-crystalline; anda third polymer layer comprising said at least one polymer layer in dry powder form.6. The pharmaceutical product of claim 1 ...

Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment

A method for delivering an immunotherapy agent to a tumor includes advancing the delivery device into a vessel of a patient, and infusing the agent under pressure into the vessel to penetrate the tumor. The delivery device prevents reflux of the agent toward non-treatment sites.

Formulations for Tailored Drug Release

The present invention provides formulations comprising polymers and therapeutics and methods for their manufacture. The present invention also provides medical devices coated with such formulations and methods for their manufacture. The drug-loaded polymer formulations, solutions, and films tailor the drug release characteristics for medical devices. 1. A formulation comprising:a biocompatible hydrophilic polymer having a thickness of between about 1 μm and about 1 mm and an elastic modulus of between about 0.05 MPa and about 1000 MPa; anda therapeutic disposed within the hydrophilic polymer,wherein the polymer provides for release of about 0% to about 30% the therapeutic within about 1 minute after introduction of the formulation into physiological conditions, and wherein the polymer provides for release of at least about 50% to about 100% of the therapeutic within about 20 minutes after introduction of the formulation into physiological conditions.2. The formulation of wherein the release is measured using high performance liquid chromatography (HPLC).3. The formulation of claim 1 , wherein the polymer comprises poly(ethylene oxide) (PEO) claim 1 , heparin claim 1 , dextran claim 1 , dextran sulfate (DS) claim 1 , polyethylene glycol (PEG) claim 1 , butyryl trihexyl citrate (BTC) claim 1 , heparin sulfate (HS) claim 1 , hyaluronic acid (HA) claim 1 , chondroitin sulfate (CS) claim 1 , or combinations thereof.4. The formulation of claim 1 , wherein the polymer is present at a concentration of between about 1 μg/mmand 2000 μg/mm.5. The formulation of claim 1 , wherein the polymer thickness is between about 50 μm and about 500 μm.6. The formulation of claim 1 , wherein the polymer is PEO claim 1 , and wherein the PEO has an average molecular weight range of between about 100 Da and about 10 claim 1 ,000 claim 1 ,000 Da.7. A formulation comprising:poly(ethylene oxide) (PEO) having (a) a thickness of between about 1 μm and about 1 mm; (b) an average molecular weight ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE AND PROCESSES FOR MIXING FIBRINOGEN AND THROMBIN WHILE PRESERVING FIBRIN-FORMING ABILITY, COMPOSITIONS PRODUCED BY THESE PROCESSES, AND THE USE THEREOF

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing for treating wounded tissue in a mammal , said solid dressing comprising at least one haemostatic layer having a wound facing surface and an opposite surface , and consisting essentially of fibrinogen and a solvent consisting of water and a fibrinogen activator , wherein said haemostatic layer is substantially homogenous , and wherein said fibrinogen is present in an amount about 13.0 mg/cmof the wound facing surface of said dressing , and wherein the moisture content of said solid dressing is from 6% to 44%.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a backing material.4. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin cross-linker and/or a source of calcium ions.5. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.6. The solid dressing of claim 1 , wherein said haemostatic layer is cast as a single piece.7. The solid dressing of claim 1 , wherein said haemostatic layer is composed of a plurality of particles claim 1 , each of said particles consisting essentially of fibrinogen and thrombin.8. The solid dressing of claim 7 , wherein said haemostatic layer further contains at least one binding agent in an ...

Implantable Scaffolds for Treatment of Sinusitus

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. 124-. (canceled)25. A method of treatment of a human patient with chronic rhinosinusitis , comprising: i) a therapeutic-agent-containing layer comprising mometasone furoate and a biodegradable polymer material and', 'ii) a therapeutic-agent-free polymer topcoat layer, said topcoat layer positioned on said therapeutic-agent-containing layer so as to slow the release of the mometasone furoate;, 'a) providing a scaffold comprising'}b) delivering said scaffold to the middle meatus under conditions where the scaffold conforms to the middle turbinate and delivers said mometasone furoate from the middle meatus to a sinus cavity of a human patient with chronic rhinosinusitis.26. The method of claim 25 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.27. The method of claim 25 , wherein said patient has failed medical management based on the administration of oral steroids.28. The method of claim 25 , wherein said patient has failed medical management based on the administration of topical steroids.29. A method of treatment of a human patient with chronic rhinosinusitis claim 25 , comprising: i) a therapeutic-agent-containing layer comprising mometasone furoate and a biodegradable polymer material and', 'ii) a polymer topcoat layer, said topcoat layer positioned on said therapeutic-agent-containing layer so as to slow the release of the mometasone furoate;, 'a) providing a scaffold comprising'}b) delivering said scaffold to the middle meatus under conditions where the scaffold conforms to the middle turbinate and delivers said mometasone furoate from the middle meatus to a sinus cavity of a human patient with chronic rhinosinusitis.30. The method of claim 29 , wherein the scaffold delivers said mometasone furoate to the ethmoid sinuses.31. The method of claim 29 , wherein said patient has failed medical management based on the ...

POLYPEPTIDE AND HYALURONIC ACID COATINGS

The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit. 3. The polyelectrolyte coating according to claim 1 , wherein R of formula (1) is —NH—C(NH)—NH.4. The polyelectrolyte coating according to claim 1 , wherein n is 15 to 95.5. The polyelectrolyte coating according to claim 1 , which comprises 1 to 500 polycationic layers.6. The polyelectrolyte coating according to claim 1 , which comprises 1 to 500 polyanionic layers.7. A device comprising a polyelectrolyte coating according to .8. The device of claim 7 , wherein the polyelectrolyte coating covers at least a portion of the surface of said device.9. The device of claim 8 , wherein said device is an implantable device.10. The device according to claim 9 , wherein the implantable device is selected from the group comprising catheters claim 9 , arteriovenous shunts claim 9 , breast implants claim 9 , cardiac and other monitors claim 9 , cochlear implants claim 9 , defibrillators claim 9 , dental implants claim 9 , maxillofacial implants claim 9 , middle ear implants claim 9 , neurostimulators claim 9 , orthopedic devices claim 9 , pacemaker and leads claim 9 , penile implants claim 9 , prosthetic devices claim 9 , replacement joints claim 9 , spinal implants claim 9 , voice prothesis claim 9 , artificial hearts claim 9 , contact lenses claim 9 , fracture fixation device claim 9 , infusion pumps claim 9 , intracranial pressure device claim 9 , intraocular lenses claim 9 , intrauterine ...

IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. More specifically, a drug-eluting scaffold is implanted in the middle meatus to treat chronic sinusitis for weeks to months. 139-. (canceled)40. A method of treatment , comprising delivering an expandable scaffold comprising a therapeutic agent into the middle meatus of a human patient , wherein the expandable scaffold is one for which , when submersed in a pH 7.4 PBS buffer solution containing 2 wt % SDS at 37° C. under gentle shaking on a rotary shaker and the buffer solution is removed completely on a weekly basis as a sample for therapeutic agent quantification and replaced with fresh buffer ,(a) a quantity of therapeutic agent released in each sample, relative to a total amount of therapeutic agent originally in the scaffold, ranges from 1% to 10%, beginning with the second week sample and extending up to the twelfth week sample, or{'sup': '2', '(b) a quantity of therapeutic agent released per unit scaffold area in each sample, beginning with the second week sample and extending up to the twelfth week sample, ranges from 0.05 to 4 μg/mm/week, where scaffold area is equal to πDL, where D is the manufactured diameter of the scaffold and L is the manufactured length of the scaffold, or'}(c) both (a) and (b).41. The method of claim 40 , wherein the expandable scaffold is delivered to the native middle meatus using a 2 to 4 mm catheter. This application is a continuation in part of U.S. Ser. No. 15/197,686 entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS and filed Jun. 29, 2016, which claims the benefit of U.S. Provisional Application No. 62/186,030 entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS and filed Jun. 29, 2015, U.S. Provisional Application No. 62/289,982 entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS and filed Feb. 2, 2016, and U.S. Provisional Application No. 62/332,134 entitled IMPLANTABLE SCAFFOLDS FOR ...

DECELLULARIZED BIOMATERIAL FROM MAMMALIAN TISSUE

The present invention includes a growth factor profile, connective tissue matrix constituents, and immunoprivileged status of equine placental tissue extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render equine placental tissue an ideal source for biological scaffolds for xenotransplantation, and optionally adding at least one of: one or more block-copolymers, one or more osteogenic agent or one or more osteoinductive agents. 1. An acellular or decellularized biomaterial produced by the process that comprises:obtaining placental tissue from an equine animal, which tissue sample comprises an extracellular matrix, anddecellularizing the tissue sample to retain structural and functional integrity while removing sufficient cellular components of the sample to be suitable for clinical use.2. The decellularized biomaterial of claim 1 , wherein the decellularizing comprises subjecting the placental tissue to an alkaline treatment.3. The decellularized biomaterial of claim 1 , wherein the process further comprises subjecting the sample to sterilization.4. The decellularized biomaterial of claim 1 , further comprising devitalized cells.5. The decellularized biomaterial of claim 1 , further comprising adding to the acellular or decellularized biomaterial at least one of: one or more block-copolymers claim 1 , one or more osteogenic agent or one or more osteoinductive agents.6. A tissue graft comprising extracellular matrix components derived from a placental tissue from an equine animal claim 1 , wherein the graft has been processed to decellularize the tissue graft and retain structural and functional integrity.7. An isolated claim 1 , decellularized equine placental tissue extracellular membrane claim 1 , wherein the membrane is inductive and conductive and at least one of: one or more block-copolymers claim 1 , one or more osteogenic agent or one or more osteoinductive agents.8. The isolated tissue of claim ...

BIODEGRADABLE MEDICAL DEVICES AND METHOD TO CONTROL DEGRADATION OF THE BIODEGRADABLE MEDICAL DEVICES

An implantable biodegradable device having two or more layers composed of one or more biodegradable materials is disclosed. The two or more layers are coated with one or more drugs. The implantable biodegradable device further having one or more inert layers is composed of a biodegradable material. The one or more inert layers of the implantable biodegradable device are degraded in response to introduction of one or more external triggers when the implantable biodegradable medical device is placed within a living organism. Further, a layer of the two or more layers having a position above an inert layer is degraded prior to degradation of the inert layer. Subsequently, a layer of the two or more layers having a position below the inert layer is degraded subsequent to degradation of the inert layer. 1. A method of controlling degradation of an implantable biodegradable medical device placed within a living organism , the method comprising:supplying at least one external trigger to at least one inert layer of the implantable biodegradable medical device, wherein the at least one inert layer is degraded in response to supplying the at least one external trigger; anddegrading at least one layer of a plurality of layers of the implantable biodegradable medical device, the at least one layer is composed of a biodegradable material and coated with at least one drug, wherein at least one layer of the plurality of layers having a position at least one of below and above the at least one inert layer, the at least one layer having a position above the at least one inert layer degrades prior to degradation of the at least one inert layer; and the at least one layer of the plurality of layers having a position below the at least one inert layer degrades subsequent to degradation of the at least one inert layer.wherein a layer of the plurality of layers having a position above an inert layer is degraded prior to degradation of the inert layer, wherein a layer of the plurality of ...

ANTIBACTERIAL MEDICAL PRODUCT AND METHOD FOR PRODUCING SAME

The present invention relates to a medical product, comprising an antibacterial hard material coating, which is applied to a main body and which comprises biocide. Said hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant and greater than the biocide concentration in the inner layer and the biocide concentration in the inner layer is greater than or equal to 0.2 at %. 1. A method of applying a hard material coating on a main body of a medical product by a physical vapor deposition process , comprising depositing a biocide-free material applied from a first target via arc ion plating and depositing a biocide-containing material applied from a second target via magnetron sputter ion plating.2. The method of claim 1 , wherein the method is conducted in an atmosphere comprising argon and nitrogen.3. The method of claim 1 , wherein the method is conducted at a temperature of less than or equal to 300° C.4. The method of claim 1 , wherein the method is conducted at a pressure of 0.02 mbar.5. The method of claim 1 , further comprising depositing a bonding layer via arc ion plating on the main body prior to deposition of the hard material coating.6. The method of claim 5 , wherein the bonding layer has a thickness of less than or equal to 0.3 m. μm.7. The method of claim 1 , wherein the main body is subjected to mechanical or electro-chemical treatment prior to deposition of the hard material coating.8. The method of claim 1 , wherein the hard material coating comprises an inner layer and an outer layer claim 1 , wherein the inner layer is between the outer layer and the main body claim 1 , the outer layer has a biocide concentration (bcI) of 2 at % to 15 at % claim 1 , and the inner layer has a biocide concentration (bcII) that is greater than or equal to 0.2 at % and less than bcI.9. The method according to claim 8 , wherein bcI and bcII are controlled by varying an arc ...

Process for the Production of Storable Implants with an Ultrahydrophilic Surface

The present invention concerns a process for the production of implants with an ultrahydrophilic surface as well as the implants produced in that way and also processes for the production of loaded, so-called bioactive implant surfaces of metallic or ceramic materials, which are used for implants such as artificial bones, joints, dental implants or also very small implants, for example what are referred to as stents, as well as implants which are further produced in accordance with the processes and which as so-called “delivery devices” allow controlled liberation, for example by way of dissociation, of the bioactive molecules from the implant materials. 1. A storable implant , comprising:an implant material having an ultrahydrophilic surface, wherein said implant material is selected from the group consisting of metallic materials, pure titanium, metallic titanium alloys, chromium/nickel/aluminium/vanadium/cobalt alloys, TiAlV4, TiAlFe2,5, high-quality steels, V2A, V4A, chromium-nickel 316 L, ceramic materials, hydroxyapatite, aluminium oxide, and combinations of the metallic materials with ceramic materials,wherein said ultrahydrophilic surface comprises an oxide layer, andwherein said ultrahydrophilic surface further comprises an exsiccation layer.2. The storable implant of claim 1 , wherein the exsiccation layer covers at least the ultrahydrophilic surface and has a layer thickness of 1 to 500 μm.3. The storable implant of claim 1 , wherein the exsiccation layer encloses the ultrahydrophilic surface on all sides.4. The storable implant of claim 1 , wherein the ultrahydrophilic surface is sterile.5. A process for the production of a storable implant with an ultrahydrophilic surface claim 1 , comprising:providing an implant with dynamic contact angles from 0° to 10° upon wetting of the ultrahydrophilic surface of the implant with water,placing the implant into a salt-containing aqueous solution which is inert in relation to the ultrahydrophilic surface and which ...

Drug delivery medical device

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on said substrate, wherein said coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of said medical device in the body of said subject a portion of said pharmaceutical agent and/or active biological agent is delivered at said intervention site along with at least a portion of said polymer and/or a at least a portion of said pharmaceutical carrying agents.

WATER-VAPOR-PERMEABLE ADHESIVE BANDAGES

The present invention relates to adhesive bandages provided with a water-vapor permeable back layer and an adhesive layer, in which the adhesive layer includes 10 weight percent of a disperse internal phase of hydrophilic particles that are water-swellable in an outer phase that includes at least 10 weight percent of a styrene block copolymer and at least 20 weight percent of an ester resin of colophony, and that can further contain at least one anti-virus substance. 1. A skin plaster comprising a water-vapor-permeable back layer and an adhesive layer which comprises at least 10% by weight of hydrophilic , water-swellable particles as a dispersed inner phase within an external phase adhesive composition comprising a styrene isoprene block copolymer and a glycol ester of dehydrogenated colophony , wherein said copolymer is at least 10% by weight of said adhesive and said ester resin of colophony is at least 20% by weight of said adhesive ,{'sup': 2', '2, 'the skin plaster exhibits a water vapor permeability in a period of 24 hours of between at least 50 g/mto less than 1000 g/m,'}and adhesive power sufficient to cover cut or graze wounds.2. The skin plaster as claimed in claim 1 , wherein the styrene isoprene block copolymer is the only copolymer in the adhesive composition.3. The skin plaster as claimed in claim 1 , wherein the ester resin of colophony is an ester of one or more resin acids.4. The skin plaster as claimed in claim 3 , wherein the ester of one or more resin acids is at least one of an ester of abiotic acid or an ester of pimaric acid.5. The skin plaster as claimed in claim 1 , wherein the hydrophilic claim 1 , water-swellable particles are hydrocolloids.6. The skin plaster as claimed in claim 1 , wherein the hydrophilic claim 1 , water-swellable particles comprise compounds selected from the group consisting of starch flour claim 1 , celluloses claim 1 , chitosan claim 1 , pectin claim 1 , gum arabic claim 1 , guar seed flour claim 1 , carob seed ...

ANTIBACTERIAL MEDICAL PRODUCT AND METHOD FOR PRODUCING SAME

A medical product including an antibacterial hard material coating, which is applied to a main body and which includes biocide. The hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant and greater than the biocide concentration in the inner layer and the biocide concentration in the inner layer is greater than or equal to 0.2 at %. 1. A medical product with an antibacterial hard material coating comprising a biocide applied to a main body , the hard material coating comprising an inner layer and an outer layer , wherein the inner layer is between the outer layer and the main body , the outer layer has a biocide concentration (bcI) of 2 at % to 15 at % , and the inner layer has a biocide concentration (bcII) that is greater than or equal to 0.2 at % and less than bcI.21. The medical product of claim 1 , wherein the inner layer has a thickness (d) of at least 0.2 μm.32. The medical product of claim 1 , wherein the outer layer has a thickness (d) of at least 0.5 μm.4. The medical product of claim 1 , wherein bcI is substantially constant throughout the outer layer.5. The medical product of claim 1 , the hard material coating comprising one or more of TiN claim 1 , TiAlN claim 1 , AlTiN claim 1 , CrN claim 1 , WC/C or a-C:H.6. The medical product of claim 1 , further comprising a bonding layer and/or an anti-wear protection layer and/or a hard material layer between the inner layer and the main body claim 1 , wherein the bonding layer claim 1 , the anti-wear protection layer claim 1 , and the hard material layer contain essentially no biocide.7. The medical product of claim 6 , wherein the anti-wear protection layer has a hardness of greater than or equal to 1500 HV.8. The medical product of claim 1 , further comprising an intermediate layer between the inner layer and the outer layer claim 1 , wherein the intermediate layer has a biocide concentration (bcIII) that is ...

IMPLANTABLE MEDICAL DEVICE

An implantable medical device, which comprises a device substrate, a coating on the substrate which includes a drug, and a protective layer which overlies the coating. The protective layer comprises a polymer selected from the group consisting of polylactic acid, polyglycolic acid and a lactic acid/glycolic acid copolymer having a weight average molecular weight of not more than 40,000. 1. (canceled)2. An implantable medical device comprising:an orthopedic device substrate having a surface;a coating on at least a portion of the surface of the substrate, the coating comprising a water soluble antibiotic drug; and,a protective layer disposed over the coating, the protective layer comprising a biodegradable polymer that is polylactic acid or a lactic acid copolymer and having a weight average molecular weight of not more than 40,000 g/mol;wherein the device is configured to release at least 90% of the antibiotic drug within 1 week;wherein the device is configured to contact bone; and,wherein the device is configured to control infection at an orthopedic surgical site.3. The device of claim 2 , wherein the device is configured to release at least 90% of the drug within 1 day.4. The device of claim 2 , wherein the device is configured to release at least 60% of the drug within 10 hours.5. The device of claim 2 , wherein the weight average molecular weight of the polymer is less than 20 claim 2 ,000 g/mol.6. The device of claim 2 , wherein the surface of the substrate on which the coating is provided is at least in part a metal.7. The device of claim 2 , wherein the surface of the substrate on which the coating is provided includes one or more pores.8. The device of claim 2 , wherein the coating has a thickness of about less than 10 μm.9. The device of claim 2 , wherein the coating has a thickness of about less than 7 μm.10. The device of claim 2 , wherein the coating has a thickness of about less than 5 μm.11. The device of claim 2 , wherein the coating has a thickness ...

MULTI-LAYER BIOMATERIAL FOR TISSUE REGENERATION AND WOUND HEALING

The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects. 1. A composition comprising a first and second layer;the first layer comprising a porous biomaterial matrix; andthe second layer comprising a impermeable biomaterial.2. The composition of claim 1 , wherein the matrix is a structure selected from the group consisting of:foams; hydrogels; electro spun fibers; gels; fiber mats; sponges; 3-dimensional scaffolds; non-woven mats; woven materials; knit materials; fiber bundles;and fibers.3. The composition of any of - claim 1 , wherein the biomaterial is selected from the group consisting of:silk fibroin; PGA; collagen; polyethylene oxide, collagen, fibronectin, keratin, polyaspartic acid, polylysin, alginate, chitosan, chitin, and hyaluronic acid.4Bombyx mori. The composition of any of - claim 1 , wherein the silk fibroin comprises silk fibroin.5. The composition of any of - claim 1 , wherein the first and second layers comprise the same biomaterial.6. The composition of any of - claim 1 , wherein the first and second layers comprise different biomaterials.7. A composition comprising a first and second layer;the first layer comprising a porous silk fibroin matrix; andthe second layer comprising a impermeable silk fibroin film.8. The composition of any of - claim 1 , further comprising an agent.9. The composition of claim 8 , wherein the agent is selected from the group consisting of:an antibiotic; an agent to attract cells; a cell; a stem cell; a ligand; a growth factor; a platelet; and a component of extracellular matrix.10. The composition of any of - claim 8 , wherein the average pore size of the biomaterial matrix is at least 200 μm.11. The composition of any of - claim 8 , wherein the average pore ...

Pary-xylene based microfilm elution devices

This invention is in the field of controlled elution devices for therapeutic delivery. There exists a need for a stand-alone capable device for the localized and extended delivery of a therapeutic. This need is overcome by the present invention having an examplary embodiment comprised of a microfilm base ( 12 ), a reservoir of a therapeutic ( 14 ) disposed about the microfilm base ( 12 ) and a top layer ( 24 ) that is (i) a plurality of laminated layers ( 24 ) of para-xylyelne polymer and/or (ii) para-xylyelne polymer endowed with oxidatively functionalized para-xyele units. The thicknesses of the device is optimally in the range of about 10 to about 200 microns. The device is usable for the localized release of broad spectrum therapeutics for interventional and preventative medicine.

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. 1. A balloon catheter for delivering a therapeutic agent to target site in a blood vessel , the balloon catheter comprising: the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, beta-lapachone, biologically active vitamin D, and combinations thereof; and', 'the at least one first additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, PEG sorbitan palmitates, and combinations thereof; and, 'a coating layer overlying an exterior surface of a balloon, the coating layer comprising a therapeutic agent and at least one first additive, whereina biocompatible polymer.2. The balloon catheter of claim 1 , wherein the biocompatible polymer is present in an adherent layer.3. The balloon catheter of claim 2 , wherein the adherent layer is positioned between the coating layer and the exterior surface of the balloon.4. The balloon catheter of claim 1 , wherein the biocompatible polymer is selected from the group consisting of polyolefins claim 1 , polyisobutylene claim 1 , ethylene-I-olefin copolymers claim 1 , acrylic polymers claim 1 , ...

INTRACRANIAL DRUG DELIVERY MATERIALS AND METHODS

This application relates generally to the field of minimally invasive delivery of therapeutic agents. Specifically, the present invention provides for materials and methods directed to minimally invasive, targeted delivery of agents such as drugs, penetrants, blood barrier augmentation agents or other compounds to certain localized brain regions through the use of delivery balloon catheters. 110.-. (canceled)11. A medical device for intracranial delivery of therapeutic agents , the medical device comprising a balloon catheter , wherein the balloon comprises a first coating and a second coating , and further wherein the second coating is applied on top of the first coating.12. The medical device of claim 11 , wherein the first coating comprises at least one water soluble polymer.13. The medical device of claim 12 , wherein the at least one water soluble polymer comprises a globular serum protein having an approximate molecular weight of between 65-70 kD.14. The medical device of 11 claim claim 12 , wherein the second coating is comprised of a formulation having a first component and optionally a second component.17. The medical device of claim 14 , wherein the first component of the formulation consists of one of carmustine claim 14 , temozolomide claim 14 , lomustine claim 14 , procarbazine or vincristine.18. The medical device of claim 14 , wherein the second component is a non-polymer claim 14 , non-ionic claim 14 , linear hydrocarbon or surfactant selected from the group consisting of a lipoic fatty alcohol or a fatty aldehyde or a fatty acid or combinations thereof.19. The medical device of claim 18 , wherein a hydrocarbon or surfactant is a fatty alcohol having the formula CHO claim 18 , wherein x is at least 18 and at the most 35 claim 18 , and y is at least 38 and at the most 72.20. A method of treating an individual having a primary brain tumor claim 18 , the method comprising:(a) providing a balloon catheter comprising a first coating and a second coating ...

DRUG RELEASING COATINGS FOR BALLOON CATHETERS

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. 120-. (canceled)221. The balloon catheter of claim , wherein the hydrophobic therapeutic agent is paclitaxel.231. The balloon catheter of claim , wherein the hydrophobic therapeutic agent is rapamycin.241. The balloon catheter of claim , wherein the hydrophobic therapeutic agent is a combination of antioxidants and paclitaxel or rapamycin.251. The balloon catheter of claim , wherein the total drug load of the hydrophobic therapeutic agent is from 1 μg to 20 μg per square millimeter of the expandable balloon.261. The balloon catheter of claim , wherein the total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon.271. The balloon catheter of claim , wherein the first additive is a PEG sorbitan monolaurate.287. The balloon catheter of claim , wherein the PEG sorbitan monolaurate is PEG-20 sorbitan monolaurate.291. The balloon catheter of claim , wherein the first additive is a PEG sorbitan monooleate.309. The balloon catheter of claim , wherein the PEG sorbitan monooleate is PEG-20 sorbitan monooleate.311. The balloon catheter of claim , wherein the first additive is one of PEG-20 sorbitan monolaurate , PEG-20 sorbitan monooleate , or combinations thereof.321. The balloon catheter of claim , wherein the second additive is one of sorbitol , ...

DRUG RELEASING COATINGS FOR BALLOON CATHETERS

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. 120-. (canceled)221. The balloon catheter of claim , wherein the hydrophobic therapeutic agent is paclitaxel.231. The balloon catheter of claim , wherein the hydrophobic therapeutic agent is rapamycin.241. The balloon catheter of claim , wherein the hydrophobic therapeutic agent is a combination of antioxidants and paclitaxel or rapamycin.251. The balloon catheter of claim , wherein the total drug load of the hydrophobic therapeutic agent is from 1 μg to 20 μg per square millimeter of the expandable balloon.261. The balloon catheter of claim , wherein the total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon.271. The balloon catheter of claim , wherein the first additive is a PEG sorbitan monolaurate.287. The balloon catheter of claim , wherein the PEG sorbitan monolaurate is PEG-20 sorbitan monolaurate.291. The balloon catheter of claim , wherein the first additive is a PEG sorbitan monooleate.309. The balloon catheter of claim , wherein the PEG sorbitan monooleate is PEG-20 sorbitan monooleate.311. The balloon catheter of claim , wherein the first additive is one of PEG-20 sorbitan monolaurate , PEG-20 sorbitan monooleate , or combinations thereof.321. The balloon catheter of claim , wherein the second additive is one of sorbitol , ...

LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE

This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. A drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects , said drug delivery device having a reservoir comprising:i. at least one active Ingredient optionally,ii. a polyurethane based polymer completely surrounding the reservoir; and optionally,iii. at least one pharmaceutically acceptable carrier.2. The drug delivery device of claim 1 , wherein the reservoir is cylindrically shaped.3. The drug delivery device of claim 2 , wherein the polyurethane based polymer is selected from the group comprising: thermoplastic polyurethane claim 2 , and thermoset polyurethane.4. The drug delivery device of claim 2 , where the thermoplastic polyurethane is made of macrodials claim 2 , diisocyanates claim 2 , difunctional chain extenders or mixtures thereof.5. The drug delivery device of claim 2 , where the thermoset polyurethane is made of multifunctional polyols claim 2 , isocyanates claim 2 , chain extenders or mixtures thereof.6. The drug delivery device of claim 5 , where the thermoset polyurethane comprises a polymer chain and cross-linking members claim 5 , said thermoset polyurethane contains unsaturated bonds in the polymer chains and appropriate crosslinkers and/or initiators as cross-linking members.7. The drug delivery device of claim 2 , where the polyurethane comprises functional groups selected ...

METHOD FOR APPLYING CHARGED PARTICLES TO AN IMPLANT

The invention relates to a method for coating an implant (), in particular a prosthesis, by applying charged particles (T) by means of iontophoresis to at least one section () of the implant surface (). In the method, charged particles are accelerated in an electromagnetic field (E) and hit the surface () of the implant in order to form a coating on the implant at least in some sections. The charged particles have at least one active ingredient. 112-. (canceled)131020110120313313. A method for coating an implant (I) , in particular a prosthesis , by applying charged particles (T) to at least one portion ( , ; , ) of the implant surface ( , ) using iontophoresis , wherein the charged particles are accelerated in an electromagnetic field (E) and impinge on the surface ( , ) of the implant so as to form a coating on at least part of the implant , and wherein the charged particles comprise at least one active ingredient.14. The method according to claim 13 , in which the active ingredient comprises a medicament claim 13 , in particular an antibiotic.15. The method according to claim 13 , in which the active ingredient comprises a cytokine.16. The method according to claim 14 , in which the active ingredient comprises a cytokine.17. The method according to claim 13 , in which the active ingredient comprises apatite claim 13 , preferably calcium phosphate and/or hydroxylapatite.18. The method according to claim 16 , in which the active ingredient comprises apatite claim 16 , preferably calcium phosphate and/or hydroxylapatite.19. The method according to claim 13 , in which at least part of the implant surface is configured to be electrically conductive.20. The method according to claim 13 , in which at least one portion of the implant surface is formed of metal and/or polymer claim 13 , in particular polyethylene claim 13 , and or ceramic.21. The method according to claim 13 , in which the accelerating voltage for accelerating the charged particles is at least 10 V and ...

ACETABULUM FOR A HIP PROSTHESIS

The invention concerns an acetabulum for a hip prosthesis made from a biocompatible polymer, said acetabulum being covered with a coating which comprises a first layer of titanium applied to said biocompatible polymer and which further comprises, on the first layer, a second layer of titanium or of calcium phosphate, characterized in that: 1. An acetabulum for a hip prosthesis made from a biocompatible polymer , said acetabulum being covered with a coating that comprises a first layer of titanium applied on said biocompatible polymer and that further comprises , on the first layer , a second layer of titanium or of a calcium phosphate , characterized in that:a). the roughness Rt of the first layer of titanium is between 40 and 500 μm; andb). said first layer of titanium has been applied by hot compression on said biocompatible polymer.2. The acetabulum according to claim 1 , characterized in that said roughness Rt of the first layer of titanium is between 100 and 500 μm.3. The acetabulum according to claim 1 , characterized in that said coating comprises on said second layer claim 1 , when the second layer is a layer of titanium claim 1 , a third layer of a calcium phosphate.4. The acetabulum according to claim 1 , characterized in that the biocompatible polymer is selected from the group consisting of the ultra-high-molecular-weight polyethylene (UHMWPE) claim 1 , non-cross-linked claim 1 , cross-linked and/or charged with antioxidants preferably chosen among the carotenoids claim 1 , the vitamins A claim 1 , B claim 1 , C claim 1 , E (tocopherols) and K claim 1 , the polyphenols claim 1 , the BHT claim 1 , the propyl claim 1 , octyl and dodecyl gallates claim 1 , the lipoic acid claim 1 , the dihydroxylipoic acid claim 1 , the amines claim 1 , the hydroquinone claim 1 , the coenzyme Q10 and the glutathione claim 1 , the polyaryletherketone (PEAK) such as the polyetheretherketones (PEEK) claim 1 , charged or not with carbon.5. The acetabulum according to claim 1 , ...

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups. 113-. (canceled)14. A medical device for delivering a therapeutic agent to a tissue , the medical device comprising: the coating layer comprises a therapeutic agent and at least one additive;', 'the therapeutic agent is a water-insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof;', 'the at least one additive comprises at least one chemical compound having at least one amide group and chosen from urea, biuret, acetamide, lactic acid amide, aminoacid amide, acetaminophen, uric acid, polyurea, urethane, urea derivatives, niacinamide, N-methylacetamide, N,N-dimethylacetamide, sulfacetamide sodium, versetamide, lauric diethanolamide, lauric myristic diethanolamide, N,N-Bis(2-hydroxyethyl stearamide), cocamide EA, and cocamide DEA., 'a coating layer overlying an exterior surface of the medical device, wherein15. The medical device of claim 14 , wherein the at least one additive is chosen from urea claim 14 , biuret claim 14 , acetamide claim 14 , aminoacid amide claim 14 , uric acid claim 14 , polyurea claim 14 , N-methylacetamide claim 14 , N claim 14 ,N-dimethylacetamide claim ...

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

Medical devices are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers. 119-. (canceled)20. A medical device for delivering a therapeutic agent to a tissue , the medical device comprising a coating layer overlying an exterior surface of the medical device , the coating layer comprising a therapeutic agent and an additive , wherein:the medical device is a stent, a stent graft, or a balloon catheter;the therapeutic agent is a water insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, lapachone, vitamin D2, vitamin D3, and combinations thereof;the additive is an amino acid selected from the group consisting of alanine, asparagine, aspartic acid, cysteine, cystine, glycine, histidine, proline, isoleucine, leucine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, and combinations thereof.21. The medical device of claim 20 , wherein the amino acid is a low-solubility amino acid having a solubility in unbuffered water of less than 40 mg/mL claim 20 , the low-solubility amino acid being selected from the group consisting of asparagine claim 20 , aspartic acid claim 20 , cystine claim 20 , isoleucine claim 20 , leucine claim 20 , methionine claim 20 , phenylalanine claim 20 , tryptophan claim 20 , tyrosine claim 20 , and combinations thereof.22. The medical device of claim 20 , wherein the amino acid is proline.23. The medical device of claim 20 , wherein the therapeutic agent is chosen from paclitaxel claim 20 , rapamycin claim 20 , and combinations thereof.24. The medical device of claim 20 , wherein the therapeutic agent is paclitaxel and the amino acid is proline.25. The medical device of claim 20 , further ...

DRUG ELUTING EXPANDABLE DEVICES

The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices. 147.-. (canceled)48. A drug eluting device comprising an expandable member and at least one coating on said expandable member comprising at least one layer , wherein said at least one layer of said at least one coating comprises an adjustable matrix composition comprising a sol gel material and a bioactive material , wherein the expandable member is a basket.49. The drug eluting device of claim 48 , wherein said basket comprises a material that comprises a shape memory metal claim 48 , shape memory metal alloy claim 48 , or a superelastic material.50. The drug eluting device of claim 49 , wherein the material is nickel titanium.51. The drug eluting device of claim 48 , wherein the basket is self-expanding.52. The drug eluting device of claim 48 , wherein the basket is manually expanding.53. The drug eluting device of claim 48 , wherein the basket comprises a metal claim 48 , polymer claim 48 , ceramic or other blends or combinations thereof.54. The drug eluting device of claim 48 , wherein the bioactive material comprises at least one of an anti-restenotic agent claim 48 , an anti-inflammatory agent claim 48 , an HMG-CoA reductase inhibitor claim 48 , an antimicrobial agent claim 48 , an antineoplastic agent claim 48 , an angiogenic agent claim 48 , an anti-angiogenic agent claim 48 , a thrombolytic agent claim 48 , an antihypertensive agent claim 48 , an anti-arrhythmic agent claim 48 , a calcium channel blocker claim 48 , a cholesterol-lowering agent claim 48 , a psychoactive agent claim 48 , an anti-depressive agent claim 48 , an anti-seizure agent claim 48 , a contraceptive claim 48 , an analgesic claim 48 , ...

BIODEGRADABLE POLYMER AND TISSUE COMBINATIONS

A biodegradable bioprosthesis can include a biodegradable tissue and a biodegradable polymer combined with the biodegradable tissue. The biodegradable tissue can be non-crosslinked tissue, EDC crosslinked tissue or tissue crosslinked using biodegradable crosslinker. The biodegradable polymer can be a crosslinked polymer and/or synthetic polymer. The bioprosthesis can include a bioactive agent (rifampin). The biodegradable tissue and biodegradable polymer can form a drug delivery patch having the bioactive agent. The bioactive agent can be an antimicrobial. The biodegradable tissue can be decellularized. A method of making the biodegradable bioprosthesis can include treating the biodegradable tissue with a fluid having the biodegradable polymer. A method of implanting a biodegradable bioprosthesis can include implanting the bioprosthesis in a subject, where the bioprosthesis is implanted for repairing a hernia and/or the bioprosthesis inhibits post-operative adhesions. 1. A biodegradable bioprosthesis comprising:a biodegradable tissue; anda biodegradable polymer combined with the biodegradable tissue.2. The bioprosthesis of claim 1 , wherein the biodegradable tissue is non-crosslinked tissue claim 1 , EDC crosslinked tissue or tissue crosslinked using biodegradable crosslinker.3. The bioprosthesis of claim 1 , wherein the biodegradable polymer is selected from polylactones claim 1 , polyhydroxy acids claim 1 , polylactide poly-L-lactides (PLLA) claim 1 , poly-D-lactides (PDLA) claim 1 , poly-DL-Lactides (PLA) claim 1 , polyglycolides (PGA) claim 1 , polylactide-polyglycolide copolymers; polydioxanones claim 1 , polycaprolactones (PCL) claim 1 , polyhydroxyalkanoates claim 1 , poly(3-hydroxybutyrate) claim 1 , 3-hydroxyvalerate claim 1 , 4-hydroxybutarate claim 1 , 3-hydroxyhexanoate claim 1 , 3-hydroxyoctanoate claim 1 , polycaprolactone-polyglycolide copolymers claim 1 , polyethylene oxides claim 1 , polylactone-polyethylene oxide copolymers claim 1 , modified ...

IMPLANT WITH AN BIOACTIVE COATING AND METHOD FOR PROVIDING THE SAME

The present invention relates to an implant having a surface comprising a coating on at least a portion of the surface of the implant, wherein the coating comprises at least two coating layers of bioactive compounds adjacent to each other, obtainable in a process comprising the following steps: providing an implant with a surface, providing a first suspension comprising at least one first bioactive compound in a first solvent, wherein the first bioactive compound is non-soluble or partially soluble in the first solvent, applying said first suspension comprising the at least one first bioactive compound onto at least a part of the implant surface forming a first coating layer; drying the first coating layer, providing a second solution comprising at least one second bioactive compound in a second solvent, wherein the second bioactive compound is soluble or readily soluble in the second solvent; applying said second solution comprising the at least one second bioactive compound onto the first coating layer forming a second coating layer, and drying the second coating layer. 1. An implant having a surface comprising a coating on at least a portion of the surface of the implant , wherein the coating comprises at least two coating layers of bioactive compounds adjacent to each other , the implant obtainable in a process comprising the steps of:providing an implant with a surface;providing a first suspension comprising at least one first bioactive compound in a first solvent, wherein the first bioactive compound is non-soluble or partially soluble in the first solvent;applying said first suspension comprising the at least one first bioactive compound onto at least a part of the implant surface forming a first coating layer;drying the first coating layer;providing a second solution comprising at least one second bioactive compound in a second solvent, wherein the second bioactive compound is soluble or readily soluble in the second solvent;applying said second solution ...

Coating of a Vascular Endoprosthesis

The invention relates to a method for coating a vascular endoprosthesis, wherein the outside of the vascular endoprosthesis is wetted at least partially with a first solution of an active substance, the vascular endoprosthesis is moved in a rotational movement about the longitudinal axis of the vascular endoprosthesis, and a radially acting mechanical force is applied to the outside of the vascular endoprosthesis. The rotational movement has the effect that the solution is carried outward by the centrifugal force, such that no active substance deposits in the interior of the vascular endoprosthesis. The application of a mechanical force to the outside of the vascular endoprosthesis then has the effect of creating crystallization nuclei, such that the active substance can crystallize out. 1. A method for coating a vascular endoprostheis , said method comprising the following steps:a) at least a partial wetting of the outside of the vascular endoprosthesis with a first solution of an active substance;b) moving the vascular endoprosthesis into a rotational movement about the longitudinal axis of the vascular endoprosthesis;c) applying a radially acting mechanical force on the outside of the vascular endoprosthesis.2. The method according to claim 1 , further comprising;applying the radially acting mechanical force to the outside of the vascular endoprosthesis by rolling the vascular endoprosthesis over a surface by exerting a pressure.3. The method according to claim 2 , further comprising;applying the radially acting mechanical force to the outside of the vascular endoprosthesis by rolling the vascular endoprosthesis over an elastomer surface.4. The method according to claim 3 , further comprising applying the radially acting mechanical force to the outside of the vascular endoprosthesis by rolling the vascular endoprosthesis over a rubber surface.5. The method according to claim 1 , further comprising;moving the vascular endoprosthesis into a rotational movement ...

PROGESTERONE-CONTAINING COMPOSITIONS AND DEVICES

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices. 1. A drug eluting medical device comprising:a medical device;an eluting mechanism selected from the group consisting of a coating, reservoir, pore, duct, channel, chamber, side-port, and lumen; anda composition consisting essentially of (i) progesterone or a progesterone analog or (ii) progesterone or a progesterone analog and one or more of vitamin E and conjugated linoleic acid; the medical device comprises the eluting mechanism;', 'the eluting mechanism elutes the composition;', 'the progesterone is present in a therapeutically effective amount; and', 'the progesterone is eluted in vivo., 'wherein'}2. The device of claim 1 , wherein:the eluting mechanism is proximal to, distal to, lateral to, underneath, embedded within or on the device; andthe eluting mechanism elutes progesterone in vivo.3. The device of claim 1 , comprising at least one coating layer; wherein:the at least one coating layer comprises the composition; andthe at least one coating layer is formed on at least a portion of a surface of the medical device.4. The device of claim 1 , wherein the composition ...

MEDICAL IMPLANT

The present invention relates to a cell-free, multi-layered medical device having bespoke, multifunctional bioactivity for the purpose of regeneration of skeletal tissues. The medical device may actively promote homing of stem cells into the medical device and promote their differentiation into the required cell type and promote de-novo tissue formation. The invention includes methods of making the medical device, uses of the medical device in promoting regeneration of the articular cartilage of a joint surface and in promoting healing and regeneration of skeletal tissues, for example, meniscal cartilage, tendon and ligament tissues and also healing of bone tissue indications such as fractures. 1. A biomimetic medical device comprising a scaffold coated in or adsorbed on its surfaces with a first layer comprising a cationic agent , the first layer being covered or coated with a second layer comprising an anionic oligosaccharide or polysulphated moiety , which is non-covalently bound to at least one or more bioactive factors selected from the groups comprising:(i) an agent that can stimulate stem cell differentiation and/or promote appropriate extracellular matrix formation for the tissue to be regenerated;(ii) an agent that inhibits enzymes associated with the breakdown or catabolism of extracellular matrix; and(iii) a stem cell homing or migratory factor.2. A device according to wherein the first and second layers are non-covalently bound together.3. A device according to either or wherein the scaffold is synthetic or natural.4. A device according to wherein the scaffold material is selected from the group comprising polyester compositions claim 3 , polylactic acid claim 3 , polylactic acid-glycolic acid copolymer compositions claim 3 , polycaprolactone claim 3 , polyester-polyallylamine copolymers claim 3 , collagens claim 3 , peptides claim 3 , silks claim 3 , chitosan claim 3 , hyaluronan-based polymers claim 3 , decellularised tissue claim 3 , calcium phosphate ...

Stents Having Biodegradable Layers

Provided herein is a coated coronary stent, comprising: a. stent framework; b. a plurality of layers deposited on said stent framework to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form. 1. A method of preparing a coronary stent comprising:a. providing a stent framework;b. depositing a plurality of layers on said stent framework to form said coronary stent; wherein at least one of said layers comprises a drug-polymer coating wherein at least part of the drug is in crystalline form and the polymer is a bioabsorbable polymer.2. The method of claim 1 , wherein the drug and polymer are in the same layer; in separate layers or in overlapping layers.3. The method of claim 1 , wherein the stent framework is made of a material selected form the group consisting of stainless steel claim 1 , a metal alloy claim 1 , and a cobalt chromium alloy.4. The method of wherein the stent framework is formed from a material comprising the following percentages by weight: 0.05-0.15 C claim 1 , 1.00-2.00 Mn claim 1 , 0.040 Si claim 1 , 0.030 P claim 1 , 0.3 S claim 1 , 19.00-21.00 Cr claim 1 , 9.00-11.00 Ni claim 1 , 14.00-16.00 W claim 1 , 3.00 Fe claim 1 , and Bal. Co.5. The method of claim 1 , wherein the stent framework has a thickness of about 50% or less of a thickness of the coronary stent.6. The method of claim 1 , wherein the stent framework has a thickness of about 100 μm or less.7. The method of claim 1 , wherein said bioabsorbable polymer is selected from the group consisting of PGA poly(glycolide) claim 1 , LPLA poly(l-lactide) claim 1 , DLPLA poly(dl-lactide) claim 1 , PCL poly(e-caprolactone) PDO claim 1 , poly(dioxolane) PGA-TMC claim 1 , 85/15 DLPLG p(dl-lactide-co-glycolide) claim 1 , 75/25 DLPL claim 1 , 65/35 DLPLG claim 1 , 50/50 DLPLG claim 1 , TMC poly(trimethylcarbonate) claim 1 , p(CPP: ...

Coatings Containing Multiple Drugs

A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents. 1a. a core, andb. a coating deposited on said core, said coating comprising at least one polymer layer in dry powder form, andc. at least one pharmaceutical layer comprising a pharmaceutical agent having a morphology that is crystalline or semi-crystalline.. A pharmaceutical product comprising: The present application is a continuation application of U.S. patent application Ser. No. 16/223,552, filed on Dec. 18, 2018, which is a continuation of U.S. patent application Ser. No. 15/591,287, filed on May 10, 2017, which is a continuation of U.S. patent application Ser. No. 14/969,884, filed on Dec. 15, 2015 (now U.S. Pat. No. 9,737,645), which is a continuation of U.S. patent application Ser. No. 14/473,741, filed on Aug. 29, 2014, now U.S. Pat. No. 9,415,142, the disclosures of which are hereby incorporated by reference, which claims the benefit of U.S. application Ser. No. 12/298,459, filed Mar. 16, 2009, now U.S. Pat. No. 8,852,625, which was filed pursuant to 35 U.S.C. § 371 as a United States National Phase Application of International Application No. PCT/US2007/010227, filed Apr. 26, 2007, which claims the benefit of U.S. Provisional Application Nos. 60/912,394 filed Apr. 17, 2007; 60/745,731 filed Apr. 26, 2006; and 60/745,733 filed Apr. 26, 2006, all of which are incorporated herein by reference in their entirety.The present invention relates to methods for depositing a coating comprising a polymer and a pharmaceutical or biological agent in powder form onto a substrate.It is often beneficial to provide coatings onto ...

IMPLANT WITH ANTIPROLIFERATIVE ACTIVE SUBSTANCE LIMITED TO ABLUMINAL SIDE AND METHOD OF PRODUCTION

An implant, such as an endovascular implant, has degradable main body that defines a lumen. A degradable coating including at least one degradable polymer substantially completely encloses the main body on its luminal and abluminal sides. An antiproliferative active substance is upon the degradable coating only on the abluminal side of the main body. 1. An implant , comprising:a degradable main body defining a lumen;a degradable coating comprising at least one degradable polymer, the degradable coating substantially completely enclosing the main body on its luminal and abluminal sides; andan antiproliferative active substance upon the degradable coating only on the abluminal side of the main body.2. The implant according to claim 1 , wherein the degradable coating comprises polylactic acid and/or poly(lactide-co-glycolide) claim 1 , and/or poly-ε-caprolactone.3. The implant according to claim 1 , wherein the antiproliferative active substance is an mTOR inhibitor or a cytostatic agent.5. The implant according to claim 1 , wherein the degradable coating comprises poly(L-lactic acid) having an inherent viscosity in the range from 0.5 dl/g to 4.0 dl/g.6. The implant according to claim 1 , wherein the main body comprises a degradable alloy.7. The implant according to claim 1 , wherein the main body substantially consists of magnesium or a degradable magnesium alloy.8. The implant according to claim 1 , wherein the main body has the form of a hollow cylindrical mesh.9. The implant according to claim 1 , wherein the implant is an endovascular implant.10. A method for producing an implant claim 1 , comprising the steps:providing a degradable main body defining a lumen,applying a degradable coating comprising at least one degradable polymer substantially to the entire surface of the degradable main body on is luminal and abluminal sides,applying an antiproliferative active substance to the degradable coating only the abluminal side of the main body.11. The method according ...

MEDICAL DEVICE RAPID DRUG RELEASING COATINGS COMPRISING A THERAPEUTIC AGENT AND A CONTRAST AGENT

The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, a contrast agent, and an additive. 120.-. (canceled)21. A balloon catheter for delivering a therapeutic agent to a target site in a blood vessel , the balloon catheter comprising a coating layer overlying an exterior surface of a balloon of the balloon catheter , the coating layer comprising a therapeutic agent and at least one first additive , wherein:the balloon catheter is a scoring balloon catheter;the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, beta-lapachone, biologically active vitamin D, and combinations thereof; andthe at least one first additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, PEG sorbitan palmitates, and combinations thereof.22. The balloon catheter of claim 21 , wherein the coating layer is dried.23. The balloon catheter of claim 21 , wherein the coating layer further comprises a contrast agent chosen from iobitridol claim 21 , iohexol claim 21 , iomeprol claim 21 , iopamidol claim 21 , iopentol claim 21 , iopromide claim 21 , ioversol claim 21 , ioxilan claim 21 , iotrolan claim 21 , iodixanol claim 21 , and ioxaglate claim 21 , and their derivatives.24. The balloon catheter of claim 23 , wherein the coating layer consists essentially of the therapeutic agent claim 23 , the contrast agent claim 23 , and the at least one first additive.25. The balloon catheter of claim 23 , wherein the coating layer further comprises a hydrophilic second additive selected from the group consisting of polyglyceryl-10 oleate ...

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups. 113.-. (canceled)14. A medical device for delivering a therapeutic agent to a tissue , the medical device comprising a coating layer overlying an exterior surface of the medical device , the dried coating layer comprising a hydrophobic therapeutic agent , a first additive , wherein:the hydrophobic therapeutic agent is a water-insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof; andthe first additive is selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, and combinations thereof.15. The medical device of claim 14 , wherein the coating layer further comprises a second additive selected from the group consisting of sorbitol claim 14 , sorbitan claim 14 , xylitol claim 14 , gluconolactone claim 14 , and combinations thereof.16. The medical device of claim 15 , wherein the coating layer further comprises an antioxidant comprising propyl gallate.17. The medical device of claim 15 , wherein:the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof.18. The ...

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups. 118-. (canceled)19. A balloon catheter for delivering a therapeutic agent to a target site of a body lumen chosen from an esophagus , an airway , a sinus , a trachea , a colon , a biliary tract , a urinary tract , or a prostate , the balloon catheter comprising a balloon and a coating layer overlying external surfaces of the balloon , wherein:the coating layer comprises a water-soluble first additive and a hydrophobic therapeutic agent;the hydrophobic therapeutic agent is chosen from paclitaxel, rapamycin, everolimus, docetaxel, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, or combinations thereof; andthe water-soluble first additive comprises gluconolactone or a PEG fatty ester chosen from PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates.20. The balloon catheter of claim 19 , wherein the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate claim 19 , PEG-20 sorbitan monopalmitate claim 19 , PEG-20 sorbitan monostearate ...

ANTI-THROMBOGENIC GRAFTS

The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof. 1. A composition comprising a substrate having at least one surface coated with an anti-thrombogenic coating comprising thiol-modified hyaluronic acid.2. The composition of claim 1 , wherein the anti-thrombogenic coating is crosslinked to the at least one surface of the substrate.3. The composition of claim 1 , wherein the anti-thrombogenic coating comprises a therapeutic agent.4. The composition of claim 1 , wherein the substrate is decellularized tissue.5. The composition of claim 4 , wherein the decellularized tissue is a decellularized blood vessel having a luminal surface claim 4 , and wherein the anti-thrombogenic coating is coated on the luminal surface of the decellularized blood vessel.6. A method of preparing a graft coated with an anti-thrombogenic coating comprising thiol-modified hyaluronic acid claim 4 , comprising the steps of:providing a substrate having at least one surface; andcoating the at least one surface with an anti-thrombogenic coating, wherein said step of coating comprises:applying a first crosslinking solution to the surface; andapplying a hydrogel solution to the surface, thereby providing an anti-thrombogenic coating on the surface of the substrate, wherein the hydrogel solution comprises thiol-modified hyaluronic acid.7. The method of claim 6 , wherein the substrate is decellularized tissue.8. The method of claim 7 , wherein the decellularized tissue is a decellularized blood vessel.9. A method of treating a diseased blood vessel in a subject claim 7 , comprising bypassing the diseased blood vessel by implanting into ...

DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES

Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein. 1. A drug delivery coating comprisinga base polymeric layer, the base polymeric layer comprising a hydrophilic surface; a particulate hydrophobic therapeutic agent; and', 'a cationic agent, the cationic agent comprising polyethyleneimine (PEI);', 'wherein a ratio (wt./wt.) of particulate hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 90/10., 'a therapeutic agent layer forming an exterior surface the drug delivery coating, the therapeutic agent layer contacting the hydrophilic surface of the base polymeric layer and having a composition different than the base polymeric layer, the therapeutic agent layer comprising'}2. The drug delivery coating of claim 1 , wherein the ratio (wt./wt.) of particulate hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 95/5.3. The drug delivery coating of claim 1 , wherein the ratio (wt./wt.) of particulate hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 98/2.4. The drug delivery coating of claim 1 , wherein the ratio (wt./wt.) of particulate hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 99/1.5. The drug delivery coating of claim 1 , the cationic agent comprising a polyethyleneimine (PEI) homopolymer or copolymer.6. The drug delivery coating of claim 5 , the copolymer comprising a PEG block.7. The drug delivery coating of ...

Scalable Microfluidic Based Artificial Skin

A scalable microfluidic based artificial skin covers a variety of wounds while also providing efficient healing of the wounds. The artificial skin comprises a plurality of microfluidic panels separated by semi-permeable membranes, and also comprising a plurality of micro-pumps and micro-channels for carrying healing fluids in proximity to the wound on the natural skin. The panels form detachable patches that are inert and biocompatible. The panels are fabricated from polydimethylsiloxane materials and impregnated with silver nanocrystalline powder. A first panel partially engages the natural skin, partially supported by micro-pillars. Large micro-channels carry contaminants from the wound. A second panel and an optional third panel having micro-channels that carry healing fluids to the wound. A first and second semi-permeable membrane regulate passage of fluids, cellular components, and debris between the panels. An inlet port enables passage of healing fluids to the wound. An outlet port enables discharge of contaminants. 1. A scalable microfluidic based artificial skin for covering , and protection while supporting and promoting proper and rapid healing of different types of wounds including chronic wounds and non-healing wounds on natural skin , the artificial skin comprising:a first panel, the first panel comprising a plurality of micro-pillars, the plurality of micro-pillars configured to enable support of the first panel on a natural skin, whereby the first panel is configured to partially engage the natural skin, the first panel further comprising a plurality of large micro-channels, the plurality of large micro-channels configured to enable carrying of a contaminant and a cellular component from the natural skin, the first panel defined by a polymeric organosilicon compound, the polymeric organosilicon compound having a nanocrystalline silver compound;a second panel, the second panel disposed generally adjacent and coplanar to the first panel, the second ...

Formulations for Tailored Drug Release

The present invention provides formulations comprising polymers and therapeutics and methods for their manufacture. The present invention also provides medical devices coated with such formulations and methods for their manufacture. The drug-loaded polymer formulations, solutions, and films tailor the drug release characteristics for medical devices. 1. A formulation comprising:poly(ethylene oxide) (PEO) having (a) a thickness of between about 1 μm and about 1 mm; (b) an average molecular weight range of between about 50,000 and about 200,000; and (c) an elastic modulus of between about 0.05 MPa and about 1000 MPa; anda therapeutic disposed within the PEO.2. A formulation comprising:dextran sulfate (DS) having (a) a thickness of between about 1 μm and about 1 mm; (b) an average molecular weight range of between about 100,000 Da and about 1,000,000 Da; and (c) an elastic modulus of between about 0.05 MPa and about 1000 MPa; anda therapeutic disposed within the DS.3. The formulation of claim 1 , wherein the PEO is between about 100 μm and about 250 μm in thickness.4. The formulation of claim 1 , wherein the PEO comprises a plurality of PEO layers including at least a first PEO layer and a second PEO layer claim 1 , wherein the first PEO layer provides for release of about 10% to about 60% of the therapeutic within about 4 minutes after introduction of the formulation into physiological conditions claim 1 , and the second PEO layer provides for release of at least about another 10% to about 60% of the therapeutic within 8 minutes after introduction of the formulation into physiological conditions.5. The formulation of claim 4 , wherein the PEO further comprises a third PEO layer claim 4 , wherein the third PEO layer provides for release of at least about another about 10% to about 60% of the therapeutic within about 12 minutes after introduction of the formulation into physiological conditions.6. The formulation of claim 4 , wherein the formulation further comprises an ...

Process for the Production of Storable Implants with an Ultrahydrophilic Surface

The present invention concerns a process for the production of implants with an ultrahydrophilic surface as well as the implants produced in that way and also processes for the production of loaded, so-called bioactive implant surfaces of metallic or ceramic materials, which are used for implants such as artificial bones, joints, dental implants or also very small implants, for example what are referred to as stents, as well as implants which are further produced in accordance with the processes and which as so-called “delivery devices” allow controlled liberation, for example by way of dissociation, of the bioactive molecules from the implant materials. 1. A process for the production of a storable implant with an ultrahydrophilic surface , the process comprising the steps of:providing an implant with an ultrahydrophilic surface with dynamic contact angles from 0° to 10° upon wetting of the surface of the implant with water,placing the implant into a salt-containing aqueous solution, which is inert in relation to the surface and which encloses the implant on all sides, andevaporating the salt-containing aqueous solution to dryness under formation of an exsiccation layer that stabilizes and protects the surface of the implant.2. The process of claim 1 , wherein the salt-containing aqueous solution has a total ion concentration of more than 0.5 mol/l.3. The process of claim 1 , wherein the salt-containing aqueous solution has a total ion concentration of more than 1 mol/l.4. The process of claim 1 , wherein the step of evaporation affords a salt layer covering at least the ultrahydrophilic surface of the implant.5. The process of claim 4 , wherein the salt layer has a layer thickness of 1 to 500 μm.6. The process of claim 1 , wherein the step of evaporation gives a salt layer enclosing the implant on all sides.7. The process of claim 1 , comprising the additional step of sterilization of the implant.8. The process of claim 7 , wherein sterilization of the implant ...

MULTIFUNCTIONAL COMPOSITE DRUG COATING SUSTAINED RELEASE SYSTEM AND METHOD FOR MANUFACTURING SAME

A multifunctional composite drug coating sustained release system includes a transition layer and a drug-loaded degradable coating, wherein the transition layer is a ceramic transition layer having different porosities and the transition layer includes a dense lower layer and a porous upper layer. The multifunctional composite drug coating sustained release system is helpful to internal fixation and also has an antibacterial efficacy. A method for manufacturing the multifunctional composite drug coating sustained release system is also disclosed which includes: preparing a biocompatible ceramic transition layer on a metal surface; and then preparing a drug-loaded degradable coating on a surface of the biocompatible ceramic transition layer. 1. A multifunctional composite drug coating sustained release system , comprising a transition layer and a degradable coating containing a drug , wherein the transition layer is a ceramic transition layer having different porosities , and further wherein the transition layer comprises a dense lower layer and a porous upper layer.2. The multifunctional composite drug coating sustained release system of claim 1 , wherein the ceramic transition layer is a TiOtransition layer claim 1 , Mg(OH)transition layer or MgO transition layer.3. The multifunctional composite drug coating sustained release system of claim 1 , wherein the porous upper layer has a pore diameter ranging from 100 nm to 3 μm.4. The multifunctional composite drug coating sustained release system of claim 1 , wherein the transition layer is disposed on a surface of an alloy matrix formed of titanium and/or magnesium.5. The multifunctional composite drug coating sustained release system of claim 1 , wherein in case of an orthopedic implant claim 1 , the drug is one or a mixture of antibacterial drugs claim 1 , and wherein in case of a cardiovascular stent claim 1 , the drug is one or more selected from a group consisting of anticancer drugs claim 1 , anticoagulants ...

BIOABSORBABLE STENT

Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher. 1. A stent comprising a core structure of a bioabsorbable material , a first coating layer of a first polymer with biodegradability , and a second coating layer of a second polymer with biodegradability , whereinthe first coating layer covers the whole surface of the core structure;the second coating layer covers a part or the whole surface of the first coating layer;the first polymer has a glass transition point of lower than 37° C.; andthe second polymer has a glass transition point of 47° C. or higher.2. The stent according to claim 1 , wherein the bioabsorbable material comprises a magnesium alloy.3. The stent according to claim 1 , wherein each of the first coating layer and the second coating layer has a film thickness of from 1 to 5 μm.4. The stent according to claim 1 , wherein the second coating layer of the second polymer contains an intimal thickening inhibitor.5. The stent according to claim 4 , wherein the intimal thickening inhibitor is sirolimus claim 4 , everolimus claim 4 , biolimus A9 claim 4 , zotarolimus claim 4 , and/or paclitaxel.6. The stent according to claim 1 , wherein each of the first polymer and the second polymer has a number average molecular weight of 30000 to 200000.7. The stent according to claim 1 , wherein the combination of the first polymer and the second polymer ...

Materials For Soft And Hard Tissue Repair

Biomaterials and methods and uses for repair or augmentation of tissues are provided. In particular, the invention provides a multi-layered, naturally occurring multi-axial oriented biomaterial comprising predominately type I collagen fibers. The invention further provides methods and uses for repair or augmentation of tissues using biomaterials of the invention. 1selecting naturally-occurring muscular fascia comprising multi-layered, multi-axial oriented biomaterial that mimics composition and structure of tissue to be repaired or augmented, wherein the muscular fascia includes type I collagen fibers;configuring the selected muscular fascia to provide a ball burst strain of between 5% and 35%; andcrosslinking one or more layers of the muscular fascia to obtain a crosslinked biomaterial that mimics a mechanical characteristic of the tissue to be repaired or augmented,wherein the selected muscular fascia includes type I collagen fibers within each layer that are axially aligned in different directions from other type I collagen fibers within the each layer,wherein the muscular fascia is a xenograft or allograft with respect to a recipient of the biomaterial.. A method for manufacture of a biomaterial suitable for tissue repair or augmentation, comprising: This application is a continuation of copending U.S. application Ser. No. 15/445,955, filed Feb. 28, 2017, which was a continuation of now-abandoned U.S. application Ser. No. 13/406,424, which was filed on Feb. 27, 2012 and which claimed priority from U.S. Provisional Application No. 61/446,956, filed on Feb. 25, 2011, and from U.S. Provisional Application No. 61/515,803, filed on Aug. 5, 2011, the entire content of which applications are incorporated herein by reference as if fully set forth below in its entirety and for all applicable purposes.The invention relates to biomaterials and methods and uses for tissue repair or augmentation.Collagen rich, naturally derived tissue has been used to repair hernias and ...

DRUG ELUTING STENT AND METHOD OF USE OF THE SAME FOR ENABLING RESTORATION OF FUNCTIONAL ENDOTHELIAL CELL LAYERS

The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipateldisappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE. 1. A drug eluting stent , comprising:a stent framework;a drug-containing layer;a drug embedded in the drug-containing layer; anda biocompatible base layer disposed over the stent framework and supporting the drug-containing layer,wherein the drug-containing layer has an uneven coating thickness, wherein a thickness of the drug-containing layer on a luminal side of the stent and a thickness of the drug-containing layer on a lateral side of the stent is less than a thickness of the drug-containing layer on an abluminal side of the stent;wherein said drug-containing layer and said biocompatible base layer are interpenetrated, forming an interdigitated interface without chemical bonding or layering.23-. (canceled)4. The drug eluting stent of claim 1 , where the ratio between the thickness of the drug-containing layer on the luminal side and the thickness of the drug-containing layer on the abluminal side is between 2:3 and 1:7.5. The drug eluting stent of claim 1 , where the ratio between the thickness of the drug-containing layer on the lateral side and ...

COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION

One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling. 1. A method of treating a chronic wound comprising administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages , wherein the sequential conversion of the wound macrophages promotes tissue remodeling.2. The method of claim 1 , wherein the delivery system is a composition selected from the group consisting of: a hydrocolloid composition claim 1 , a hydrogel claim 1 , a polysaccharide-based composition claim 1 , a semi-permeable polymeric adhesive film composition claim 1 , a foam composition claim 1 , a biological composition claim 1 , a polymeric scaffold claim 1 , a sequential controlled-release delivery system claim 1 , and a layer-by-layer delivery system.3. The method of claim 1 , wherein the delivery system comprises IL-4 bound to the delivery system through a binding molecule.4. The method of claim 3 , wherein the binding molecule is non-covalently bound to the delivery system.5. The method of claim 3 , wherein the IL-4 is covalently bound to an affinity molecule that interacts with the binding molecule.6. The method of claim 3 , wherein the IL-4 is released by dissociating the IL-4 from the binding molecule.7. The method of claim 3 , wherein the delivery system further comprises IL-10 bound to the delivery system through a binding molecule.8. The method of claim 7 , wherein the IL-10 is bound to an affinity molecule that interacts with the binding molecule ...